Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 1 of 73Clinical Research Protocol
A PHASE I, SINGLE CENTER, OPEN LABEL, SINGLE DOSE, DOSE ESCALATION STUDY 
ASSESSING THE SAFETY AND TOLERABILITY OF ALLOGENEIC MESENCHYMAL STEM CELL 
INFUSION IN ADULTS WITH CYSTIC FIBROSIS-CEASE CF
Protocol Number: CF-MSC-01 
Version Number: Version 1.13
Version Date: 17Dec2019
Investigational Product: Mesenchymal Stem  Cells
IND Number: 16822
Development Phase: I
Funding Source: Cystic Fibrosis Foundation Therapeutics
6931 Arlington Road, 2nd floor
Bethesda, MD 20814
Sponsor- Investigator: Erica A. Roesch, M.D.
Telephone: 216-844-3267
Fax: 216-844-5916
E-mail: erica.roesch@uhhospitals.org U3 
Medical Monitor: TDNCC Medical Monitoring  Group
Pager: ( 800) 341-0961
Fax:(206) 985-3278
Coordinating Center: Rainbow Babies  and Children’s Hospital/Case  Western 
Reserve University School of Medicine
Cleveland, OH 44106
Telephone: 216-844-3267
Fax: 216-844-1841 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 2 of 73Approval:
Erica A.  Roesch, M.D. DateParticipating Laboratories:
University Hospital  Cleveland Medical  Center Laboratories 
11100 Euclid Avenue
Cleveland, OH 44106
Center for Interpretive  Cytology at Case  Western Reserve 
University
11100 Euclid Avenue, Wearn 611
Cleveland, OH 44106
Bioanalyte Core
Department of Pediatric Pulmonology 
Case Western Reserve University
Biomedical Research Building 
10900 Euclid Avenue
Cleveland, OH 44106
Center for Human Genetics Laboratory of University Hospitals Cleveland Medical Center
W.O. Walker  Center, 6th floor
10524 Euclid Avenue
Cleveland, OH 44106
Indiana Blood Center
Testing Laboratory
3450 N. Meridian Street
Indianapolis, IN 46208
National Center for Regenerative Medicine (NCRM) Cellular Therapy  Laboratory
2103 Cornell Road,  WRB 6-303
Cleveland, OH 44106
Charles River  Laboratory
358 Technology Drive
Malvern, PA 19355
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 3 of 73This confidential information about  an investigational drug is provided for the 
exclusive use of  investigators of this drug  and is subject to recall at any time.   The  
information in  this document  may not be disclosed unless  federal or state law or 
regulations require such disclosure.  Subject to the foregoing, this  information  may 
be disclosed only to those  persons  involved in the study who have a need to know, 
with the obligation not to further disseminate this information.  These restrictions 
on disclosure  will apply equally to all future oral or written information, supplied to 
you by the Cystic Fibrosis Foundation,  which is designated as  "privileged" or 
"confidential".
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 4 of 73PROTOCOL AGREEMENT
I have read the protocol specified below. In my formal capacity as Investigator, my  duties include  ensuring the  
safety of  the study subjects enrolled under my supervision and  providing the Cystic Fibrosis  Foundation with 
complete and timely information,  as outlined in the protocol.  It  is understood that  all information pertaining to 
the study will be  held  strictly confidential and that  this confidentiality requirement applies  to all  study staff at 
this site. Furthermore,  on behalf of the  study  staff  and myself, I agree to maintain  the procedures  required  to 
carry out the study in accordance with  accepted GCP principles and to  abide by the terms of this  protocol.
Protocol Number:  CF-MSC-01 
Protocol Title:   A Phase I, Single Center,  Open Label, Single Dose, Dose  Escalation  Study  Assessing  the Safety 
and Tolerability of Allogenei C MEsenchymA l Stem  CEll Infusion in  Adults with  Cystic 
Fibrosis-CEASE CF
Protocol Version:  Version  1.13
Protocol Date:  December  17, 2019
Investigator Signature  Date
Print Name and Title
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 5 of 73TABLE OF CONTENTS
31TLIST OF ABBREVIATIONS 31T 7
31TPROTOCOL SYNOPSIS 31T 9
31T131T 31TBACKGROUND31T 15
31T1.131T 31TIntroduction31T ....................................................................................................................... 15
31T1.231T 31TSpecific Aim31T ...................................................................................................................... 15
31T1.331T 31TSignificance31T ....................................................................................................................... 15
31T231T 31TSTUDY RATIONALE 31T 25
31T2.131T 31TRisk / Benefit Assessment31T ................................................................................................. 26
31T331T 31TSTUDY OBJECTIVES31T 27
31T3.131T 31TPrimary  Objective31T .............................................................................................................. 27
31T3.231T 31TSecondary Objectives31T ........................................................................................................ 27
31T3.331T 31TImplications for  Future Studies 31T......................................................................................... 28
31T431T 31TSTUDY DESIGN 31T 28
31T4.131T 31TStudy Overview31T ................................................................................................................. 28
31T531T 31TCRITERIA FOR EVALUATION31T 29
31T5.131T 31TPrimary  Endpoint 31T............................................................................................................... 29
31T5.231T 31TSecondary Endpoints31T ......................................................................................................... 30
31T631T 31TSUBJECT SELECTION31T 30
31T6.131T 31TStudy Population31T ............................................................................................................... 30
31T6.231T 31TInclusion  Criteria 31T............................................................................................................... 30
31T6.331T 31TExclusion Criteria31T .............................................................................................................. 31
31T731T 31TCONCURRENT MEDICATIONS31T 32
31T7.131T 31TAllowed31T ............................................................................................................................. 32
31T7.231T 31TProhibited31T .......................................................................................................................... 32
31T831T 31TSTUDY TREATMENTS31T 33
31T8.131T 31TMethod of  Assigning  Subjects to Treatment Groups31T ........................................................ 33
31T8.231T 31TBlinding31T ............................................................................................................................. 33
31T8.331T 31TTest and Control Formulation31T ........................................................................................... 33
31T8.431T 31TSupply of Investigational Product at the  Site31T .................................................................... 36
31T8.531T 31TInvestigational Product Accountability31T ............................................................................. 36
31T8.631T 31TMeasures of Treatment  Compliance31T .................................................................................. 36
31T931T 31TSTUDY PROCEDURES AND GUIDELINES31T 36
31T9.131T 31TClinical Assessments 31T......................................................................................................... 37
31T9.231T 31TClinical Laboratory  Measurements 31T................................................................................... 40
31T9.331T 31TResearch  Assessments 31T....................................................................................................... 40
31T9.431T 31TScreening Assessments for  Bone  Marrow Collection31T ....................................................... 41
31T1031T 31TEVALUATIONS BY  VISIT31T 42
31T10.131T 31TVisit  1 (Screening Visit: Day  -42 to -10) 31T.......................................................................... 42
31T10.231T 31TVisit  1A (if applicable, Optional Bone  Marrow Aspiration)31T ............................................. 43
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 6 of 7331T10.331T 31TFollow-up Phone Call (if applicable, 24 (± 12)  hours after Optional Bone  Marrow 
Aspiration)31T ................................................................................................................................... 43
31T10.431T 31TVisit  2 (Baseline  Visit: Day 1)31T .......................................................................................... 44
31T10.531T 31TVisit  2 (Baseline  Visit: Day 2)31T .......................................................................................... 45
31T10.631T 31TTelephone  Call 1 (Day 4 or 5)31T ........................................................................................... 45
31T10.731T 31TVisit  3 (Day  7 ± 2)31T ............................................................................................................. 45
31T10.831T 31TVisit  4 (Day  14 ± 2)31T ........................................................................................................... 46
31T10.931T 31TTelephone  Call 2 (Day 21 ± 2)31T .......................................................................................... 47
31T10.1031T ........................................................................................................................................... 31TVisit 5 (Day 28 ± 2)31T
47
31T10.1131T ........................................................................................................................................... 31TTelephone Call 3 (Day 
56 ± 2)31T .......................................................................................................................................... 47
31T10.1231T ........................................................................................................................................... 31TVisit 6 (Month 3 ± 14 
days)31T 48
31T10.1331T ........................................................................................................................................... 31TVisit 7 (Month 6 ± 14 
days)31T 48
31T10.1431T ........................................................................................................................................... 31TTelephone Call 4 
(Month 12 ± 1)31T ............................................................................................................................. 49
31T10.1531T ........................................................................................................................................... 31TAcute  Illness/Early  
Termination Visit31T ......................................................................................................................... 49
31T10.1631T ........................................................................................................................................... 31TVisit 1 (Screening 
Visit: Day -30  to -7) 31T..................................................................................................................... 49
31T10.1731T ........................................................................................................................................... 31TVisit 2 (Bone Marrow 
Aspiration)31T ................................................................................................................................... 50
31T10.1831T ........................................................................................................................................... 31TFollow-up Phone Call 
(24 (±  12) hours after  Bone Marrow Aspiration)31T ......................................................................... 50
31T1131T 31TADVERSE EXPERIENCE REPORTING  AND DOCUMENTATION31T 50
31T11.131T 31TAdverse Events 31T.................................................................................................................. 50
31T11.231T 31TSerious Adverse Events (SAE)31T .......................................................................................... 52
31T11.331T 31TMedical Monitoring31T ........................................................................................................... 53
31T1231T 31TDISCONTINUATION AND REPLACEMENT OF SUBJECTS31T 53
31T12.131T 31TWithdrawal  of Subjects  and Drop-outs 31T............................................................................. 53
31T1331T 31TPROTOCOL VIOLATIONS31T 53
31T1431T 31TDATA SAFETY MONITORING 31T 54
31T1531T 31TSTATISTICAL METHODS AND CONSIDERATIONS  (BASED UPON PRIMARY  
AND SECONDARY  ENDPOINTS) 31T 54
31T15.131T 31TData Sets Analyzed31T ............................................................................................................ 54
31T15.231T 31TDemographic  and Baseline Characteristics 31T....................................................................... 54
31T15.331T 31TAnalysis of Primary  Endpoint31T ........................................................................................... 54
31T15.431T 31TAnalysis of Secondary/Exploratory Endpoints31T ................................................................. 55
31T15.531T 31TInterim Analysis31T ................................................................................................................ 55
31T15.631T 31TSample Size 31T....................................................................................................................... 55
31T1631T 31TDATA COLLECTION, RETENTION AND MONITORING31T 55
31T16.131T 31TData Collection  Instruments31T .............................................................................................. 55
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 7 of 7331T16.231T 31TData Management  Procedures31T ........................................................................................... 55
31T16.331T 31TData Quality Control and Reporting31T .................................................................................. 55
31T16.431T 31TArchival of Data31T ................................................................................................................ 56
31T16.531T 31TAvailability and  Retention of Investigational  Records31T ..................................................... 56
31T16.631T 31TMonitoring31T ......................................................................................................................... 56
31T16.731T 31TSubject Confidentiality 31T...................................................................................................... 56
31T1731T 31TADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS31T 56
31T17.131T 31TProtocol Amendments 31T....................................................................................................... 56
31T17.231T 31TInstitutional Review  Board31T ................................................................................................ 57
31T17.331T 31TInformed Consent Form31T .................................................................................................... 57
31T17.431T 31TPublications31T ....................................................................................................................... 58
31T17.531T 31TInvestigator Responsibilities31T ............................................................................................. 58
31T1831T 31TAPPENDIX I: DEFINITION  OF A PULMONARY EXACERBATION (MODIFIED  
FUCHS CRITERIA)P95
P31T 59
31T1931T 31TAPPENDIX II.   SCHEDULE OF  STUDY VISITS31T 60
31TAPPENDIX IIA.  SCHEDULE  OF STUDY VISITS FOR OPTIONAL STEM CELL 
COLLECTION FROM  CF SUBJECT DONORS31T 63
31TAPPENDIX IIB.  SCHEDULE OF  STUDY VISITS FOR STEM CELL 
COLLECTION FROM  HEALTHY VOLUNTEER DONORS31T 64
31T2031T 31TREFERENCES31T 65
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 8 of 73LIST OF ABBREVIATIONS
ADL Activities of daily  living
AE Adverse experience
ALT Alanine aminotransferase
AST Aspartate aminotransferase
BAL Bronchoalveolar lavage
BM
BMM
BPDBone marrow
Bone marrow macrophages
Bronchopulmonary dysplasia
BUN Blood urea nitrogen
CBC Complete blood  count
CCC Comprehensive Cancer Center
CF Cystic fibrosis
CFR Code of Federal Regulations
CFRSD Cystic Fibrosis Respiratory Symptom Diary
CFTR Cystic fibrosis transmembrane conductance  regulator
COPD Chronic obstructive  pulmonary disease
CRF Case report form
CRP C-reactive protein
CTCAE Common terminology criteria  for adverse events
CWRU Case Western Reserve University
DCRU Dahms Clinical Research Unit
DHQ Donor History Questionnaire
DLT Dose limiting toxicity
DMC Data Monitoring Committee
DMSO Dimethylsulfoxide
DSMB Data Safety Monitoring Board
ESR Erythrocyte sedimentation rate
FBS Fetal bovine serum
FDA Food and Drug Administration
FEFR 25%-75% Forced expiratory flow
FEVR 1 Forced expiratory volume  over one second
FVC Forced vital  capacity
GCP Good Clinical  Practice
GGT Gamma-glutamyl transferase
GM-CSF Granulocyte-macrophage colony-stimulating factor
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 9 of 73GVHD Graft versus  host disease
HIPAA Health Insurance Portability and Accountability  Act of 1996
HIV Human immunodeficiency virus
hMSC Human mesenchymal  stem cell
hs-CRP High sensitivity C-reactive protein
ICF Informed consent form
ICH International Conference on Harmonization
IL Interleukin
IRB Institutional Review  Board
IV Intravenous
LDH Lactate dehydrogenase
LPS Lipopolysaccharide
mEq Milliequivalent
MHC Major histocompatability  complex
MIP-3 Macrophage inflammatory protein-3 alpha
MMP-9 Matrix metalloproteinase-9
MPO Myeloperoxidase
MRSA Methicillin-resistant Staphylococcus  aureus
MSC Mesenchymal stem cell
MTD Maximum tolerated  dose
NCI National Cancer  Institute
NCRM National Center for Regenerative Medicine
PBSC Peripheral blood  stem  cell
PI Principal Investigator
QPIT Quantitative pilocarpine iontophoresis test
RC Research Coordinator
RSSQ Respiratory and Systemic Symptoms Questionnaire
SAE Serious adverse  experience
SGOT Serum glutamic oxaloacetic transaminase
SGPT
SOPSerum glutamate pyruvate  transaminase
Standard operating procedure
TDNCC
TGF-Therapeutics Development Network Coordinating Center
Transforming growth factor-beta
TNF- Tumor necrosis  factor-alpha
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 10 of 73PROTOCOL SYNOPSIS
TITLE A Phase  I, Single  Center, Open Label, Single Dose, Dose Escalation 
Study Assessing the  Safety and Tolerability of AllogeneiC 
MEsenchym Al Stem CEll  Infusion in Adults with Cystic F ibrosis-
CEASE CF
SPONSOR-INVESTIGATOR
Erica A. Roesch, M.D.
NUMBER OF SITES 1
RATIONALE Cystic fibrosis (CF) is  a genetically  inherited  disease which  impacts  
sodium and chloride transport across  the epithelium  leading to viscous 
mucus retention, chronic  bacterial infection  and relentless inflammation 
in the lung; the main  cause of morbidity and  mortality in  this disease.   
Although new  therapeutics have  been promising, new and innovative  
approaches to controlling inflammation  and bacterial  burden  in the lungs 
of these patients is  important towards minimizing the  consequences of 
the disease and improving survival.  We have published pre-clinical studies demonstrating that  human allogeneic bone  marrow derived  
human mesenchymal  stem cells (hMSCs) may provide a new therapeutic 
treatment for CF lung disease,  attenuating  pulmonary inflammation 
while decreasing bacterial growth and  enhancing antibiotic efficiency.
STUDY DESIGN This will be a prospective, single-center, dose-escalation, open-label interventional study  to evaluate the safety and  tolerability of allogeneic 
hMSCs in 15 clinically stable subjects  with CF  age ≥ 18 years. After  a 
two to six  week  screening  period, subjects will have a Baseline visit 
(Days 1-2) where  they  will undergo  a single intravenous infusion of up 
to 5 x 10P6
P allogeneic hMSCs/kg of body weight. Infusions will be 
performed in the  Dahms Clinical Research Unit (DCRU)  of University 
Hospitals Cleveland Medical Center.   Subjects will be monitored for any 
infusion related  toxicities  for 24 hours after the infusion.  Subsequent 
study visits will occur on Days 7, 14, 28, Months 3 and 6 and telephone calls will  occur on Days 4 (or 5),  21, 56 and Month 12.  Subject safety 
and tolerability of a single  dose of  hMSCs will be evaluated at study 
visits by review of subject diaries, interval history, pulmonary exacerbations (standardized definition  in Appendix I), physical 
examination, spirometry, and analysis  of safety  laboratories. Special 
attention will be  placed  upon detecting pulmonary exacerbations 
because anti-inflammatory therapies theoretically  could suppress the 
immune system to the  point where it leads to increased infectious  
complications, although MSC therapeutics are  proposed to be  
antimicrobial.  In addition  to evaluating  safety,  this study will also  
explore efficacy end-points for future  clinical trials of MSCs in CF 
including inflammatory biomarkers from blood and sputum.  Serum  
markers  (calprotectin, MPO, GM-CSF, IL-1β, IL-6, IL8, IL-17, and  
TNF-) and sputum  markers (white  cell counts and  differentials, IL-1β, 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 11 of 73IL-6, IL-8, IL-10, IL-17, GM-CSF, MIP-3, TNF- , and active 
proteases including neutrophil elastase, R 1R-anti-trypsin, and MMP-9) 
will be determined at Baseline  and on Days 7 and 28 for  with-in subject  
comparison.  All subject samples will be archived  for future  projects.   
Finally, a diagnostic bone marrow  exam  will be performed on subjects 
with CF who consent to undergo  the procedure.  Bone marrow  samples  
will be banked  and used for future translational studies. Study-related 
procedures are outlined  in Appendix II.
PRIMARY OBJECTIVE
To evaluate the infusion-related safety  and tolerability of a single 
allogeneic hMSC infusion in adults with CF. 
SECONDARY OBJECTIVES
To explore preliminary  evidence for the  potential  efficacy  of 
MSCs as a new therapeutic  to treat  CF pulmonary infection and 
inflammation as measured by
oChange in sputum inflammatory markers
oChange in serum  inflammatory markers
To compare allogeneic MSCs to autologous MSCs in  a 
preclinical model.  The potential efficacy  of MSCs obtained from  
CF subjects who agree to undergo  the optional bone marrow 
aspiration will be  evaluated in validated animal models. 
NUMBER OF SUBJECTS
15 subjects with cystic fibrosis  for main study
1-2 healthy volunteer subjects for  bone marrow  donation only
Throughout protocol, “subject” refers to subject  with cystic  fibrosis 
unless otherwise specified.
SUBJECT SELECTION
CRITERIAInclusion Criteria: 
1.Male or female 18 years of age and above
2.Confirmed diagnosis of CF as evidenced by 1 or more clinical features 
consistent with the CF phenotype and 1 or more of the following 
criteria:
a.Sweat chloride equal to or  greater than 60 mEq/L by 
quantitative pilocarpine iontophoresis test (QPIT) 
b.2 well-characterized, disease causing  mutations in the 
CFTR gene 
3.Clinically stable with no significant changes in health status within 2 
weeks prior to  screening 
4.FEVR 1 R≥ 40% predicted  for age based on the  global lung  function 
initiative equations  at the screening visit 
5.Weight ≥ 40 kg at the screening visit
6.Able to perform repeatable, consistent efforts in pulmonary function 
testing
7.Written informed consent  obtained from the subject
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 12 of 73Exclusion Criteria: 
1.Use of an investigational agent  within the 4-week  period prior to Visit 
1 (Day -42 to -10)
2.Chronic daily  (>10 mg) or alternate  daily (>20 mg on alternate days) 
use of systemic corticosteroids  within the 4 weeks prior to Visit 1 (Day  
-42 to -10) or initiation of any dosage of systemic corticosteroids 
within 72 hours prior to Visit 2 (Day 1)  
3.Use of hydroxychloroquine or immunosuppressants 
4.Initiation of a new antibiotic  (oral, IV, and/or inhaled) that is  not part 
of the subject’s maintenance regimen  for treatment of acute 
respiratory symptoms within  2 weeks prior  to screening through Visit 
2 (Day 1)
5.Initiation of any new chronic therapy  (e.g.,  PulmozymeP®
P, hypertonic  
saline, KalydecoP®
P, OrkambiP®
P, high-dose ibuprofen, azithromycin, 
TOBIP®
P, CaystonP®
P, nebulized colistin, bronchodilators, inhaled 
corticosteroids, etc.)  within  4 weeks  prior to screening
6.Active treatment for  non-tuberculous Mycobacteria 
7.History of a sputum culture  positive for a Burkholderia cepacia  
complex organism  in the previous 12 months 
8.Current tobacco smoker
9.Oxygen saturation <  92% on room air  at Visit 1 (Day -42 to -10)
10.History of pulmonary  hypertension
11.SGOT (ALT) or SGPT (AST) > 2.5 times the upper limit of normal at 
screening, documented biliary cirrhosis,  or portal hypertension  
12.Total  bilirubin  concentration > 1.2 mg/dL at  screening
13.Creatinine  > 1.8 mg/dL at screening
14.Pregnant, breastfeeding, or unwilling to practice birth control between 
Visit 2 (Day 1) and Telephone Call 3 (Day 56) (acceptable forms of 
contraception: abstinence, hormonal  birth control,  intrauterine device, 
or barrier  method plus a spermicidal  agent), unless surgically  
sterilized or postmenopausal
15.Screening  hematology with white blood cell count < 4.5 x 10P9
P cells/L, 
hematocrit <  30%,  and platelets  < 150 x 10P9
P platelets/L 
16.History of invasive  cancer requiring  systemic therapy 
17.History of organ transplantation
18.Currently listed for lung transplantation or having potential to be listed  
for lung transplantation in the succeeding  12 calendar months  from  
screening
19.Subject unlikely  to complete the study  as determined by the 
Investigator
TEST PRODUCT,  Single Infusion of up to 5 x 10P6
P allogeneic MSCs/kg of body weight.  A  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 13 of 73DOSE AND  MODE  OF 
ADMINISTRATIONdose escalation using the  “3+3” design P1
P will be employed. The three 
doses are 1 x 106, 3 x 106, and 5 x 106 hMSCs/kg. 
Allogeneic MSCs will be  derived from bone marrow  aspirates  from a 
healthy donor whose  serum tests negative for cytomegalovirus (CMV) 
antibodies.   Healthy donors will undergo tests for infectious disease and screening for 41 common CFTR  mutations.  In  addition, the MSCs will 
be validated for in  vitro  and in vivo  efficacy and potency using the in 
vivo murine pre-clinical model of CF lung infection  and inflammation.
CONTROL PRODUCT, DOSE AND MODE OF  
ADMINISTRATION
NA
DURATION OF SUBJECT PARTICIPATION AND DURATION OF STUDY
Subjects will be  studied for approximately 13 months
Screening:  between  10 and 42 days
Treatment:  1 day  
Follow-up: 12 months
We anticipate 15 months to recruit subjects (due to the 3+3 safety study design). The  last subject in each cohort  must finish Visit 5 before  
enrolling the first subject in the next  cohort.  
ECONCOMITANT MEDICATIONS
For those on alternate month  TOBI® or Cayston® therapy, on/off cycles  
must be timed  such that  a subject is at the  same phase of a cycle at Visits 
2-5.
Allowed: All routine  chronic CF medications.  
Prohibited: Anti-inflammatory  medications (hydroxychloroquine, 
corticosteroids >10mg daily or >20  mg on alternate days) and 
immunosuppressants between Visits 1 and 5. Changes in  chronic 
treatment of  CF (e.g., introduction, dose escalation, or elimination of 
chronic therapies) between Visits 1 and 5.
SAFETY EVALUATIONS
Dose-limiting toxicities,  adverse events,  including pulmonary 
exacerbations; Cystic Fibrosis Respiratory  Symptom  Diary (CFRSD); 
Respiratory and Systemic Symptoms Questionnaire (RSSQ); physical examination; assessment of vital signs, including oxygen saturation; 
spirometry, sputum bacterial  culture  (quantitative  and qualitative); 
hematology, comprehensive chemistry, erythrocyte  sedimentation rate 
(ESR), high-sensitivity C-reactive  protein (hs-CRP), and urinalysis 
PRIMARY ENDPOINT To evaluate safety and  tolerability of a single infusion of allogeneic 
hMSCs as determined by: 
Dose  limiting toxicity (DLT):  A DLT is triggered by occurrence 
in the first  24 hours after hMSC  infusion of grade  ≥3 infusion-
related allergic toxicities, which include rash, flushing,  urticaria, 
dyspnea, fever  >40°C (>104.0°F) as scored  according to the  
National Cancer  Institute (NCI) Common Terminology Criteria 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 14 of 73for Adverse Events (CTCAE) version  4.0 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Incidence  and severity of adverse events 
Number of pulmonary exacerbations (modified  Fuch’s criteria95)
Diary reports  (Cystic Fibrosis  Respiratory Symptom Diary  
(CFRSD))
Changes in subject reported symptoms as captured by the 
Respiratory and Systemic Symptoms  Questionnaire (RSSQ) from  
Baseline (Visit 2) Day 1 to Baseline  (Visit 2) Day 2, Visits 3, 4, 5, 
6 and 7 and at times  when a pulmonary exacerbation is being  
considered 
Changes in physical  examination 
Changes in vital  signs including oxygen  saturation checked  
throughout infusion
Changes in spirometry  (FEVR 1R %, FEVR 1R (Liters),  FEFR 25-75R) 
determined 30  minutes, 4 hours, and  24 hours after completion of 
infusion and from  Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 
7
Change in sputum quantitative microbiology (bacterial colony  
forming units between  Baseline to Day 7 and Day  28)
Changes in hematology, comprehensive  chemistry, ESR, hs-CRP,  
and urinalysis  results
SECONDARY ENDPOINTS
Change in blood inflammatory biomarkers from Baseline to Day 7 
and Day 28
Change in sputum inflammatory biomarkers from  Baseline  to Day 
7 and Day 28
OTHER EVALUATIONS
Bone marrow aspiration is optional.  CF bone marrow aspirates will be used to assess autologous  approaches to MSC therapeutics. 
Any sputum or serum  remaining after the study will be archived for 
future translational projects.
SAFETY MONITORING
The Therapeutics Development Network Coordinating Center (TDNCC) Medical Monitoring Group will serve  as the  medical  monitor for this 
clinical trial.  In addition,  the Cystic Fibrosis  Foundation Data Safety 
Monitoring Board (DSMB) will establish a Data  Monitoring  Committee 
(DMC) to review  data relating  to safety and  efficacy,  to conduct  and 
review interim analyses, and to ensure the  continued  scientific validity  
and merit of  the study, according  to the Cystic Fibrosis Foundation Data  
Safety Monitoring Board  Operations Manual  and a DMC Charter 
established for this  protocol. There will be 3 interim  review(s) conducted 
by the DMC for the  purpose of monitoring study conduct and assessing  
subject safety.  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 15 of 73RATIONALE FOR NUMBER OF SUBJECTS
This is  a single center Phase I study.  Enrollment of 15 subjects will be 
feasible and allow  us to ascertain  if there  are any clinically meaningful 
infusion-related adverse effects.  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 16 of 731BACKGROUND
1.1 Introduction
Cystic fibrosis (CF) lung disease begins at  birth and continues throughout life2.  While the pathogenesis 
of CF  lung disease  is complex,  excessive inflammation is a  key component of disease pathology2.   The vicious  
cycle of  airway  obstruction, chronic  bacterial  infection, and  excessive inflammation eventually  leads to 
irreversible lung damage3.  It is possible that gene modifying agents will eliminate the downstream 
pathophysiologic consequences of defective cystic fibrosis  transmembrane conductance regulator  (CFTR).   
However, it is  more likely that gene  modifying agents will reduce the pathophysiologic consequences in  the 
airway, particularly  the exaggerated  inflammatory  response and  decrease the frequency  of pulmonary  
exacerbations, but  not eliminate them  completely.  Therefore,  future treatment regimens for CF lung disease  will 
likely employ the  administration of one or  more CFTR  disease  modifying drugs  in combination with  an anti-
inflammatory drug.   Unfortunately, previously evaluated anti-inflammatory therapeutics, such as systemic  
corticosteroids and  BIIL  284 BS, have  been associated  with  side effects  or have not shown to be  efficacious,  
and dosing and  monitoring  of high-dose ibuprofen has precluded its widespread use4,5.     
Mesenchymal stem cell (MSC) based  therapies  have generated much interest  due to their  anti-
inflammatory, anti-microbial, immunomodulatory,  and regenerative properties6.  MSCs are multipotent  cells  
that secrete a variety of  bioactive  factors, which actively contribute favorably to  their environment within 
damaged tissues.  Furthermore, MSCs  exert  immunomodulatory effects by direct cell  to cell contact7,8.  Finally, 
these cells are also capable of changing in response  to cues  from  their environment. MSCs have been  evaluated  
in clinical trials of diseases  involving multiple  organ systems including bone, cartilage, lungs, pancreas, 
neurons, intestines, and  the heart  and blood vessels6.  The medicinal potency and  efficacy  of the MSCs are  
particularly useful  in scenarios of  tissue  damage, inflammation, and infection  in the lung and gut; implicating  
the power  of MSCs therapeutic  potential in CF. 
1.2 Specific Aim
To determine the  safety and tolerability  of a single  infusion of human MSCs (hMSCs) and to explore  secondary 
efficacy endpoints to determine if hMSCs  reduce inflammation in  subjects with CF. Markers of  inflammation 
will be measured in blood and sputum before and 7 and 28 days after a  single  infusion of  hMSCs in  clinically 
stable adults with CF.  
1.3 Significance
1.3.1 Mesenchymal stem cells mechanism of  action: Anti-inflammatory, immunomodulatory, and anti-
bacterial
The immunomodulatory  properties of MSCs  and their ability to  secrete anti-inflammatory cytokines  
make them ideal  for allogeneic infusion because  immunosuppressants  are not  required. For this  study,  
allogeneic hMSCs  are being utilized because  autologous  MSCs will contain  the subject’s CFTR mutations,  
which would offset  any potential  benefit.  MSCs are relatively immunoevasive; they express low levels of major  
histocompatibility complex  I (MHC-I) molecules  and do not  express  MHC-II molecules or costimulatory 
molecules such as  CD80, CD86, or CD409, suggesting that  allogeneic  MSCs can be used in the clinical setting. 
MSCs home specifically to injured tissue and  exert  their immunomodulatory activity through  the secretion of  
angiogenic (e.g., vascular  endothelial growth factor)10, anti-apoptotic  (Bcl-2)11, and  inflammatory factors  
[tumor necrosis  factor- (TNF- , interferon-γ (IFN- ), interleukin (IL)-1, -6, and -10, VEGF, hepatocyte 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 17 of 73growth factor]10,12-15, stimulation  of angiogenesis, promotion of a  secure environment for host cell recovery, and 
repair and regeneration  of injured tissue. Exogenously administered MSCs  modulate  the function of host cells at  
the site  of injury, both by cell contact-dependent and paracrine  mechanisms which  involve secretion of  specific 
mediators or transfer of cellular materials such as proteins, nucleic acids, and cell organelles  (including 
mitochondria) to injured host cells via  microvesicles16,17.  MSCs also have antibacterial properties and  inhibit  
bacterial growth  by secretion  of the antimicrobial peptide LL-3718,19.  
1.3.2 Mesenchymal stem cells are  safe
Autologous MSCs cannot be used in this clinical trial  because  the MSCs will contain two mutations in  
CFTR. Therefore  subjects  with  CF who will be enrolled in  this trial will receive infusions of allogeneic  MSCs. 
Infusions with allogeneic hMSCs has been  shown to be  safe in  follow-up periods  lasting several years in  
patients with pulmonary  disease and patients  with other inflammatory diseases including Crohn’s disease,  graft-
vs.-host disease, multiple  sclerosis, and type 1 diabetes20. Up to  1 x 107 allogeneic  hMSCs/kg  (twice the 
maximum dose that  will be used in this study) have been infused safely.  There have  not been any issues with 
infusion-related toxicities or tumor development.  Autopsy studies reveal limited residual MSCs up to 18 months 
after administration21.  A meta-analysis of clinical trials  of MSC  infusions to evaluate  safety  identified 1012 
participants with  varying clinical conditions and identified eight randomized controlled trials with  321 
subjects22.  The authors did not detect an association  between acute infusion-related toxicity,  organ system  
complications, infection, death  or malignancy, but  there was  a significant association between MSCs  and 
transient fever22.  
A significant concern in CF  patients  receiving strong anti-inflammatory  therapies  is the increased risk of 
pulmonary exacerbations.  Weiss and  colleagues performed a placebo-controlled, randomized trial  of 
mesenchymal stem cells in chronic  obstructive pulmonary  disease (COPD) where 31 subjects received  four  
monthly stem  cell infusions and  there  was no difference in  hospitalizations  for COPD exacerbations during the  
study (six  in the MSC group  and five in the  placebo  group)23.  A recent meta-analysis  did not detect an 
association between  MSC treatment  and the development  of infection22.  Preliminary data in CF  animals 
suggests improvement in infection related outcomes,  not worsening18,19. 
Another concern is  the potential for  increased risk of cancer.  Again, this has not been detected in  
clinical trials22,24. However, the potential for  malignant transformation  would not be unexpected given some  of 
the biologic similarities  between stem cells and  cancer  cells.   However, the risk of tumorigenesis  is likely  to be 
an extremely uncommon event  with current  culture  conditions where cells are harvested for therapy well before 
the cultures reach senescence20.  Another  potential risk would be if  hMSCs engraft for  long  periods of time 
which would result  in ectopic tissue formation and increase the risk of malignant  transformation  Autopsy 
studies have not detected hMSCs in MSC  recipients,  thus suggesting that  hMSCs appear  to work through  a “hit 
and run”  mechanism21.  There have  been no reports  of de novo tumor formation complicating MSC infusion in 
humans22,24.  Nevertheless,  in our protocol, cells will be passaged the minimum  number of times  to obtain 
sufficient cell yield,  thereby lessening the potential  for cytogenetic abnormalities.  In addition, CF subjects with 
a history of  invasive  cancer requiring  systemic therapy will be  excluded  from the study.
There have been  no published  clinical trials of MSCs  in CF.  A  search  of PubMed “Mesenchymal Stem 
Cells” limited to humans and clinical  trials  returns  over 200 citations, including several pulmonary studies.  
Chang and colleagues  recently published a phase  1 dose-escalation study in  9 preterm  infants at risk for 
bronchopulmonary dysplasia and found MSC infusion  to be safe and without associated serious adverse events 
(SAEs) or  dose limiting toxicities25.  A human trial of a  commercial hUCB-MSC product (PNEUMOSTEMTM) 
for neonatal bronchopulmonary dysplasia has been performed in  South  Korea and demonstrated decreased 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 18 of 73levels of inflammatory markers in tracheal secretions and less severe  respiratory disease; no long-term data  are 
available yet25. A Phase  I/II clinical trial of PNEUMOSTEMTM is currently  enrolling in the United States. 
Stem cell infusion has also been  shown to be safe  in 30 adults with  multidrug-resistant tuberculosis26, 87 
subjects with drug refractory systemic lupus erythematosus27, and 15 subjects with  Crohn’s  disease28 and has  
been found  to have clinical benefit in pediatric  patients  with  other diseases29-31. 
1.3.3 Overview of pre-clinical  data of  MSCs  in cystic fibrosis
Dr. Bonfield’s (Co-I) laboratory carries out studies using in  vivo modeling of acute and chronic 
Pseudomonas aeruginosa (clinical isolate:  M5715) infection in mice deficient in Cftr32-34.  This murine model  
was used to evaluate  hMSCs.  Importantly, hMSCs attenuated weight loss,  clinical score  and lung pathology  
associated with  chronic  infection with P. aeruginosa in comparison to CF  mice not  treated with  hMSCs19.  In 
addition to benefits  in weight gain and overall health of the animals,  there  was a significant  decrease in  lung 
inflammation (Figure 1A).  CF  mice treated with hMSCs  had a significant reduction in BAL neutrophils  (Figure 
1A) and  bacterial burden (Figure 1B). MSC  administration also was  associated  with decreased KC  (a neutrophil  
chemoattractant), IL-6 and IL-1  concentrations  (p<.05).  These studies  also demonstrated that  MSC infusion 
was not  associated with increased  infectious complications despite  attenuating inflammation.
 
A. Percent PMNs
 B. Bacterial CFUs
Figure 1: hMSCsare Anti-inflammatory and Antimicrobial in vivo.  Cftrdeficient mice and WT controls were infected with P aeruginosaand 
followed for up to 10 days.  Mice received hMSCsone day after infection.  Animals were euthanized and evaluated for BAL neutrophils(A), and P. 
aeruginosaCFUs(B). Treatment was associatedwitha decrease in neutrophils(A, P<0.05) and bacterial CFUs (B, P<0.05).   
Bacterial infection with microorganisms, like P. aeruginosa contribute to the lung  pathophysiology in 
CF. The challenge clinically, is to attenuate the  inflammatory response that is responsible for damaging the  lung 
architecture while  at the same time not increasing infectious complications.   Figure  2 shows  an example of  
how hMSCs  impact bacterial  growth  and kinetics over time. These  studies  demonstrate that hMSC  have  
antimicrobial potential  by decreasing the overall  growth  of the bacteria.  Interestingly,  hMSCs  in combination 
with gentamicin  was even more efficient, thus suggesting  the potential to use MSC to enhance  antibiotic 
regimens for acute and/or chronic infections.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 19 of 73 
Figure 2: hMSCSupernatants are Antimicrobial.Supernatants from 4 different MSC donors were cultured with 
a clinical strain of P. aeruginosafor 5 minutes.  Bacteria were then streaked onto TSA plates and cultured 
overnight and analyzed for CFUs (A) or ATP for determination of growth kinetics (B).  Gentamicinwas used as a 
positive control.  Both gentamicinand MSC supernatants decreased CFUs (P<0.05) and rate of growth 
(P<0.05).The largest effect was seen with the combination of supernatants from hMSCsand gentamicin.
In addition  to P. aeruginosa, Dr.  Bonfield’s lab has also shown that  hMSCs have  antibacterial effects on 
Staphylococcus aureus.  Given that almost 25% of CF patients are infected  with  methicillin-resistant S. aureus 
(MRSA), which is associated with worse survival35, these  findings  are particularly noteworthy.   Dr. Bonfield  
began by evaluating  the ability  of hMSC supernatants to  change  the growth potential of S. aureus. Supernatants  
harvested from hMSCs in culture  were associated with  significantly  fewer S. aureus CFUs.   Bacterial CFUs  
were decreased further when the  hMSC supernatants were given in combination  with  antibiotics. Our laboratory  
now consistently  screens different  donor preparations for their antimicrobial potency.  These potency assays  are 
unique and were  developed here  at Case Western Reserve  University by Dr.  Bonfield.  In these in vitro potency  
and efficacy assays,  MSC preparations are cultured  with pathogens such as  P. aeruginosa, S. aureus  (including 
MRSA), and Streptococcus pneumoniae .
Cytokines are essential in the process  of leukocyte recruitment and  define the cell type and 
inflammatory response.  Wild-type and Cftr deficient epithelial cell lines were stimulated to  produce pro-
inflammatory cytokines and co-cultured  with human MSCs and then stimulated with  lipopolysaccharide  (LPS).  
Figure 3 shows the  results obtained when hMSCs  were  cultured in  cell culture  conditions with and  without 
stimulation with E. coli  LPS. In both model systems the hMSC suppressed the production  of LPS  induced  pro-
inflammatory mediators. These  cell lines are now part  of our in  vitro system  for monitoring MSC donor efficacy  
and potency in  terms of inflammation  and leukocyte recruitment.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 20 of 73 
Figure 3: hMSCsare Anti-Inflammatory.MSCs from 4 different bone marrow donors were cultured with either LPS, 
stimulated macrophages (A and B), or epithelial cells (C and D) from either CFTR-deficient or WT sources.  After 24 
hours, cells were harvested and processed for cDNAand real-time PCR.  LPS-induced IL-6 and TNF-a gene expression 
in the in macrophages was suppressed by the addition of hMSCsupernatants (P<0.05).  LPS-induced IL-6 and IL-8 gene 
expression in the epithelial cells was also suppressed by the addition of hMSC(P<0.05). BMM=bone marrow 
macrophages
1.3.4 Overview of Clinical Studies
1.3.4.1 Mesenchymal stem cells in pulmonary disease
COPD is a heterogeneous  systemic  disease  that is characterized by significant inflammation.  The only 
published study of hMSC infusion  in COPD  is the study by Weiss and  colleagues in which the infusions were  
well tolerated23.  The design was a  placebo-controlled,  randomized trial  of mesenchymal  stem cells in COPD 
where 30 subjects received four monthly stem cell infusions (100 x 106 cells) and 32 subjects received placebo.   
We propose using a  weight based  approach rather than administering a fixed dose of hMSCs.   The dose of 
MSCs that will be  used in this trial, 1 to 5 x 106 hMSCs/kg,  would be  approximately 70 to  350 x 106 hMSCs.   It 
is also important  to emphasize that these COPD subjects had  more fixed lung disease compared to  CF subjects  
with mild  to moderate CF  lung disease,  the target  population that will be  recruited  into this clinical trial.  In  
addition, subjects with COPD were older (average age 68), had moderate to severe  COPD,  and had multiple  co-
morbidities.  In this  population of subjects  with COPD,  the infusion of hMSCs was well tolerated  with  no 
differences between the  groups  in adverse  events (AEs).  No infusion-related toxicities and no SAEs occurred  
that were related  to study drug.  The  study  did not detect any  differences in pulmonary function  test results  or 
quality of  life indicators.  The  subjects with the highest levels of inflammation at baseline  had significant 
improvements in inflammatory markers compared to the placebo group, and the authors hypothesize that  
chronic immune based  inflammatory  diseases, such as CF,  may be  more  likely to respond than what was seen in  
this COPD  study. In addition, the dosing was the same  for every subject, regardless of weight.  In another 
clinical trial  of hMSC infusion  in pulmonary disease,  there was  significant efficacy seen in the  phase  1 dose-
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 21 of 73escalation study of  preterm infants with bronchopulmonary dysplasia (BPD)25.  In this  study, concentrations of  
IL-6, IL-8, MMP-9, TNF-, and transforming growth factor (TGF)-1 in tracheal aspirates at day 7 were  
significantly decreased compared to baseline  and 3 days post-infusion.   Furthermore, the severity  of BPD  was 
reduced in MSC recipients, while AEs did not differ  between the study groups.  Human studies are ongoing in 
acute respiratory distress syndrome and  idiopathic pulmonary fibrosis, but have not  been completed  or 
published. 
1.3.4.2 Infusion  of Mesenchymal Stem Cells in  Humans
MSCs have  been tested as treatment for  a variety  of clinical indications,  and in  some settings, dramatic 
benefit has  been  reported.   Hillard Lazarus,  M.D. and Arnold Caplan, Ph.D. designed and executed the very  first 
in-human MSC  trial,  which was  conducted  here at Case Western Reserve  University 36.  Since that very  first-in-
human MSC study, it is estimated that tens of thousands of subjects have  received MSCs in  over  500 trials22. 
1.3.4.3 Mesenchymal Stem Cell Trials at University Hospitals Cleveland Medical Center
1.3.4.3.1 CWRU 1494 Autologous Mesenchymal Stem Cell Infusion at the  Time of Autologous 
Peripheral Blood  Stem  Cell  Transplantation
We evaluated the feasibility  and safety of  autologous MSC infusion  in breast cancer patients undergoing  
high dose  chemotherapy and autologous peripheral  blood stem cell (PBSC) transplantation37.  We also  
investigated whether  autologous MSC  infusion at the time of PBSC  transplantation facilitated hematopoietic 
engraftment, particularly megakaryopoiesis.  In this study,  the bone  marrow (BM)  aspirate from 28 enrolled 
subjects was  successfully cultured  in excess  of 1 x 106 cells/kg (mean expansion potential 19 x 106 cells/kg).  
Subjects were  re-infused with 1-2.2 x 106 cells/kg  autologous  culture-expanded MSCs, either 24 or 1 hour after 
PBSC infusion.   Intravenous administration of MSCs was  very  well  tolerated  with no toxicity.   Neutrophil and 
platelet count recovery was  rapid  (median  days to ANC>500/l=8  days and median days to  
platelets>20,000/l=8.5 days) with none of the patients experiencing engraftment delays.  In addition, we were  
able to isolate  circulating clonogenic MSCs from the  venous blood of subjects receiving intravenous infusion of  
MSCs either  immediately  at the end of  infusion  (3 out of 15 patients),  15 minutes  after infusion  (8 out  of 15 
patients), and  60 minutes  after infusion (2 out of 15 patients).  Clonogenic MSCs were not  detected  6 and 18  
hours after infusion.   These data  indicate that MSCs  circulate for a  short period  of time following intravenous 
infusion and suggest  that they distribute widely in the  body.  Whether  these  cells  home to specific locations  or 
distribute in tissues in a  non-specific manner  is unknown.
1.3.4.3.2 OSIR 1Y98 Allogeneic  Donor Mesenchymal Stem Cell Infusion  at the Time of Allogeneic 
Peripheral Blood  Stem  Cell  or Bone Marrow Transplant
Our group led a multi-center clinical trial with MHC-identical donor allogeneic  MSCs to promote faster 
hematopoietic engraftment and to limit graft versus host  disease  (GVHD) after allogeneic BM or  PBSC 
transplantation in patients with hematological malignancies38. Forty-three subjects received  myeloablative 
chemo-radiation therapy,  MHC-identical sibling marrow (N=17) or mobilized peripheral  blood (N=26) stem  
cells, and  escalating  doses of culture-expanded MSCs from  a hematopoietic stem cell donor (1-5 x 106 cells/kg).   
There were no instances of  MSC  infusion-related  toxicities.   Median  (range)  time to neutrophil recovery 
>500/ l was 14 (11-22) days and platelets >20,000/l (not  transfused) was  21 (15-78) days for  all subjects.   
Grade 0-I  acute  GVHD occurred  in 29 subjects  and grade  II-III in  10 subjects; none had  grade  IV.  Of 36 
subjects at-risk,  chronic  GVHD  did not develop in 17  participants,  was of limited extent  in 13 subjects, and 
extensive in 6 participants.  The  expected  incidence  of acute  and chronic GVHD in  sibling-matched allogeneic 
stem cell  transplantation  varies.  In the two largest  prospective studies,  the incidence for grade  II-IV  and III-IV 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 22 of 73acute GVHD ranged  44% to  64%39and 12% to 26%40. Extensive chronic GVHD rates in  these two reports  
ranged from 30% to 46%. Our results compare  favorably with these historic data.  Despite the fact that  severe 
acute and chronic  GVHD  appeared  to be  reduced by the co-infusion of MSCs,  we did  not observe  an excessive 
number of subjects developing  tumor progression  adding confidence to the use of MSCs in  the context of non-
malignant diseases such as CF.
1.3.4.3.3 CWRU 1Y98 Late Allogeneic  Donor Mesenchymal Stem  Cell Infusion for Lysomsomal  or 
Peroxisomal Disorders
Allogeneic BM transplantation can  provide  donor cells to  correct inherited  enzymatic  deficiencies as 
well as  skeletal disorders  in non-malignant disorders41.  Many of these disorders  are only  partially  corrected  by 
an allogeneic transplantation.  We  hypothesized  that marrow derived  stromal cells could have further beneficial  
effect in these  patients by providing enzyme replacement to  the tissues to  which they distribute.  We previously 
determined that human MSCs  express high levels of arylsulfatase A  and L-Iduronidase.  Arylsulfatase A 
deficiency results in metachromatic leukodystrophy, which  is manifested during the first decade  of life with 
progressive dementia,  convulsions  and cranial nerve abnormalities.  L-Iduronidase deficiency results  in Hurler  
disease that is  manifested  by hepatosplenomegaly,  dysostosis multiplex, and neuropsychological decline.
To correct  the enzyme  deficiency and  provide  normal progenitor/stem cells to  patients with  
metachromatic leukodystrophy and Hurler  disease,  we infused  allogeneic  MSCs into these patients37.  These  
patients previously underwent allogeneic BM  transplantation from the same donor and were fully engrafted  by 
donor hematopoietic cells.  Since these  patients already had  donor type immune systems, infusion  of donor-
derived cells  of mesenchymal  lineage was expected to  be safe and  possibly provide  a therapeutic benefit.   
Subjects were  not given any myelosuppressive chemo- or radiotherapy.  Between March 1999 and  July 2000, 
12 donors were  enrolled  and MSC cultures established in  all cases.  Eleven subjects were enrolled and infused 
with donor  MSCs.   One subject dropped  out for personal reasons during the course of the investigation, after  
collection and cryopreservation of donor MSCs.  MSCs were culture-expanded in  the CWRU Cell and Gene 
Therapy Facility.  Four subjects received  2 x 106 donor  MSCs/kg,  five subjects received 3.4 to 4.6 x 106 
MSCs/kg, and three subjects received 10 x 106 MSCs/kg.  Target  donor MSCs were culture expanded in 8 
subjects.  One subject in the 4 x 106 MSCs/kg cohort  and 2 subjects in 10 x 106 MSCs/kg  cohort  received fewer  
MSCs than planned.  This was mainly due  to the excessive  time and  passage numbers that  would have  been 
required to achieve  the target  doses.  A decision was made to limit the time and the passage number in  these  
subjects.  Relatively  small amounts of starting BM aspirate and our culture conditions were adequate  to grow 10 
x 106 cells/kg  of human  MSCs for  small children  (<40kg).
There were no acute  or chronic toxicities related to donor MSC infusion  with  no significant toxicity  with 
15-31 months  of follow-up.  There  was grade  1 fever  in 3 subjects that was self-limited  in all cases.   We  have 
clinical follow-up as well  as laboratory follow-up  in all subjects.  Thus far, we have been able to re-culture 
donor MSCs from  2 recipients (0.2-2%) using the existing  culture assay technique.  We have not detected any  
immune response  against donor MSCs by ELISPOT assay using recipient lymphocytes and donor MSCs.  
Clinical outcome  was evaluated  by physical  examination  including neurological examination, psychosocial  
assessments, nerve conduction  velocity,  and bone mineral density measurements.   There was  no dramatic 
change in subjects overall health  and no readily detectable change in  mental  and physical development.  
Following allogeneic MSC  infusion, bone mineral density was either maintained or slightly improved in all  
subjects.  Five  of 6 metachromatic  leukodystrophy patients  had electrophysiological  assessment, and in  four  
there was a clear evidence of improvement  in nerve  conduction velocity.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 23 of 731.3.5 Factors  Affecting  the Characteristics  of Isolated Mesenchymal Stem Cells
The factors that  affect the characteristics of isolated  MSCs  have  not been extensively studied.  MSC 
numbers appear to decrease with age42, and MSCs  from  elderly  donors have  decreased  life span and 
proliferation rate43.  There appears  to be no age  effect on differentiation potential43. There  was little variability  
between MSCs isolated from 50 healthy  donors in proteomic profile or ability to  inhibit proliferation in mixed  
lymphocyte reaction44. 
It is uncertain  whether the functional properties  of MSCs are altered  in human diseases.  MSCs isolated 
from patients with advanced osteoarthritis had normal cell yield but  reduced  proliferation,  chondrogenic and  
adipogenic capacity45. There are  conflicting  reports on whether MSC properties are altered in  immune-mediated  
disease.  MSCs isolated from patients  with severe aplastic anemia were deficient in their ability  to inhibit T-cell  
proliferation and cytokine release,  including T-cell proliferation in allogeneic  mixed  lymphocyte reactions,  
expression of  the activation  marker  CD38 and IFN- production by phytohemagglutinin-stimulated  cells, 
production of  cyclic  ADP-ribose, and  T-cell-mediated inhibition  of hematopoietic  colony formation46.  In 1 
study, stromal progenitors isolated  from subjects with systemic sclerosis  were functionally  impaired  with  
reduced proliferation  rate and capacity for adipogenic and  osteogenic differentiation47. A similar decrease in 
proliferative potential was reported in MSCs  isolated from  26 subjects with  rheumatoid arthritis48. In contrast,  
in 2 other  studies,  MSCs  isolated from patients  with autoimmune diseases (systemic  lupus erythematosus,  
rheumatoid arthritis,  systemic sclerosis, Sjogrens syndrome,  polymyalgia rheumatica, or diabetes)  had similar  
surface phenotype, plaque-forming  ability, differentiation capacity, ability  to support hematopoiesis, and  
immunomodulatory properties as MSCs from  controls,  with  no apparent effect  of disease  activity or 
immunosuppressant therapy49,50. 
BM stromal cells isolated  from 15 MS patients had normal capacity  to support hematopoiesis, with  no 
apparent effect of recent IFN-  treatment51.  MSCs isolated from 10 multiple sclerosis (MS) patients had similar 
proliferation, differentiation capacity, toll-like  receptor expression, immunomodulatory  actions, ability to inhibit 
dendritic cell differentiation  and activation, but significantly greater LPS-stimulated  IP10  production  compared  
to 6 healthy controls52. Thus,  it is conceivable  that MSCs  from MS  patients  may have reduced 
immunomodulatory and/or repair capacity  as a manifestation of the underlying disease or its  treatment.  
Therefore, the planned studies  of the phenotype and  function of MSCs from  CF subjects as part of this  trial will 
be of great interest.
It is important  to note  that there can  be substantial variability between different MSC preparations  either  
due to donor  or specific  culture conditions53.  Key factors include freshness of the starting material, starting cell 
number, culture medium, serum or  serum substitute, the  specific plasticware used, culture  density, timing of  
passages, etc.  Experience  in our facility  and others, confirms that it is possible  to cryopreserve cells and  that 
frozen MSCs  have preserved  viability, proliferation, differentiation, and surface marker expression  and 
functionality54-56.  We plan to cryopreserve our cells  after primary culture only,  and once thawed  for culture 
they will be expanded  and infused fresh.   In our studies, specific attention  will be  given to  identifying  a donor 
MSC preparation with the highest degree  of efficacy and potency using our in vitro and in  vivo pre-clinical 
diagnostic models.   Our assays  evaluate the anti-inflammatory, antimicrobial and leukocyte recruitment 
potential of  the MSCs  in vitro followed  by validation  in our murine pre-clinical model  of CF  lung  infection and 
inflammation.
In terms of MSC preparations,  we will use our standardized protocols for culture  and expansion  of the 
identified donor cells, with the plan  to utilize the same  donor preparation for all infusions.  These specifics will  
minimize variability in the MSC  donor preparation as well as minimize any development of alloantibodies to 
the allogeneic  MSCs.   This clinical trial will utilize the standard  protocols for collecting, expanding,  
cryopreserving, and  infusing hMSCs from the  Comprehensive Cancer Center (CCC)  and the National Center  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 24 of 73for Regenerative Medicine (NCRM) at Case Western Reserve University.  At the time of infusion, an aliquot of  
MSCs that will be used in the infusion will be assessed for pre-clinical efficacy to  track any  potential changes in 
clinical potency using our in vitro pre-clinical models.  During the infusions, attention to  several factors will be 
important including minimization of prolonged  storage in the  syringe  and rapid injection through  a small-bore 
needle both of which would decrease cell  viability57.
1.3.6 Potential  Safety  Concerns
In general, MSC infusion in humans, including allogeneic MSCs,  has been very well tolerated.   
Autologous MSC  infusion is not an option for  this clinical  trial due  to the underlying genetic defect.  Neither  
acute nor  long-term clinically significant AEs attributable to  allogeneic  MSCs have been reported.  Up to  1 x 
107 cells/kg can  be infused safely  (our study will infuse  up to a maximum  of 5 x 106 cells/kg)37. There have 
been no reports of immunosuppression attributed  to MSC infusion leading to opportunistic infection or 
autoimmunity reaction.   In one clinical trial a subject  developed urticaria with  the second infusion  of allogeneic 
MSCs, thought  to be  due to development of antibodies to  the fetal bovine serum (FBS)  used  to culture MSCs58.  
FBS will  not be used in this  protocol.   There have been no reports of de  novo neoplasm in  recipients, either 
potentially derived  from  MSCs or due to a permissive  effect of MSCs.  MSCs are immune privileged and 
therefore infusion  of allogeneic  cells  is possible.  There  have been no pulmonary complications.  Nevertheless,  
several potential  adverse effects  will require  close attention.
1.3.6.1 Infusion-Related  Toxicity
During this study, we  plan  to use freshly expanded hMSCs.  By using freshly expanded hMSCs for the 
infusions, possible  infusion-related toxicities  will be reduced. However, there is a possibility that a  subject may 
be unable to get fresh hMSCs on the day of the  infusion.  In this instance,  we may infuse expanded hMSCs  that 
have been frozen  with dimethylsulfoxide (DMSO).  Most studies have reported  no infusion-related  AEs.   A 
patient with encephalopathy, stroke, and  myocardial infarction most  likely related to  DMSO  used in freezing 
medium has  been  reported59.  Anti-FBS antibodies are  common but usually not clinically significant60.  One 
study reported a  single participant who developed an urticarial  rash following a  second allogeneic MSC 
infusion58.  That participant had a 150-fold increase in  anti-FBS  antibodies after the second infusion.  Because 
MSCs are relatively  large cells  (20-60  m)61 and cell clumping is possible, pulmonary embolism is a potential  
concern.  No study has reported pulmonary symptoms, change in oxygen-saturation,  or change in  chest  
radiograph.  Adherence to established procedures for thawing and infusing  cells should minimize the potential  
for these  AEs.  
1.3.6.2 Infection
MSC infusion per se could be a  source  of infection.   MSCs could be  contaminated during harvest, 
manipulation, or infusion.  One case  series  reported a subject with  GVHD who developed central line infection 
and cellulitis62, not uncommon in critically ill patients.  Aseptic technique during BM aspiration and infusion, 
strict adherence  to culture protocols, and stringent microbiologic screening are intended  to minimize the risk  of 
administering a  contaminated cell  product. Furthermore, MSCs are potently antimicrobial  as previously 
discussed.  Therefore, using our established good laboratory  practices and  extensive  experience in  infection 
control and conduct of  clinical trials will minimize  the potential  risk of infection.
MSCs express CD13 (the cytomegalovirus  (CMV)  receptor) and to  a lesser extent CD21 (the  receptor 
for EBV)63.  MSCs can be  infected in vitro with CMV and HSV-1 but not  EBV.  Reassuringly,  CMV,  HSV-1, 
HSV-2, EBV, VZV RNAs were not detected  by PCR  in MSCs from seropositive donors.  Nevertheless, careful  
donor screening for  herpes virus, cytomegalovirus  and other infectious  agents in potential future  studies of 
allogeneic MSC infusion will remain  important.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 25 of 73Finally, because of the  immunosuppressive  actions of MSCs, recipients potentially are at increased risk 
for more  severe or opportunistic infections.   MSCs inhibit  lymphocyte  proliferative  responses  to herpes  viruses, 
candida, and S. aureus Protein A63.  MSC effects on virus-specific T-cell responses  appear to  be less than on 
other immune  responses, e.g. to alloantigens64. Infections  have occurred  in a significant proportion participants  
receiving MSC  infusion in some series.  However, all of the reported cases have involved already 
immunocompromised patients with cancer  and/or  GVHD  following HSC infusion65-67. Therefore, it is difficult 
to discern whether  MSC infusion  played a role  in the infections.   Furthermore, MSCs themselves are 
antimicrobial, producing  peptides which aide  in clearance  and managing infections.
1.3.6.3 Cancer
The potential  for malignant transformation  would not be unexpected given some of the biologic 
similarities between stem cells and cancer cells.  MSCs  in adults may become  tumorigenic68,69 and have been  
implicated in several  human or experimental tumors, including  childhood  leukemia70, gastric epithelial  
cancers71 and osteogenic sarcoma72  In the study by Tolar et al.72, the high frequency of osteogenic  sarcoma  in 
lung after MSC  infusion in  mice  appeared to be related  to the propensity of mouse cells to develop frequent  
karyotypic abnormalities  even with short-term  culture.  Karytotypic abnormalities were not  seen in some  studies 
of human  MSCs73 but were reported  in others, predominantly with prolonged culture74-76. An important  factor 
appears to be continuing  cultures following senescent  crisis77,78. 
A number of studies demonstrate homing of MSCs  to primary and  metastatic cancers where they may 
form tumor  stroma79. In addition, trophic or immunosuppressive effects  of MSCs could create a permissive  
environment for  cancer development.  For example, MSC-derived adipocytes reduced  apoptosis of acute  
promyelocytic leukemia cells  in culture80. MSCs promote  experimental breast cancer metastasis in mice81. 
Human MSCs mixed with human breast  cancer  cells  injected SC as  xenograft in mice led  to marked increase  in 
metastatic potential.   MSCs prolonged B16 melanoma  tumor cell survival when co-injected subcutaneously in 
mice82.  In a randomized trial  in hematologic  malignancy of HLA-identical sibling matched HSC  +/- MSC,  
there was decreased GVHD  in MSC  recipients (11.1%  vs. 53.3%) but  increased  leukemia  relapse (6/10  (60.0%)  
vs. 3/15  (20.0%))66. 
Despite these theoretical concerns, there  have been no reports of de novo  tumor formation complicating  
MSC infusion in humans in  the more than 500 MSC clinical trials  documented in Clinicatrials.gov.  
Nevertheless, cells will  be passaged  the minimum number of times to obtain sufficient cell yield to lessen 
potential for cytogenetic abnormalities.   Also, in this trial participants with a  history  of invasive cancer  
requiring systemic  therapy  will be  excluded.
1.3.6.4 Rejection
MSCs are immunoevasive and non-immunogenic,  which allows them to  be used in  allogeneic and 
xenogeneic transplantation.  Humans have  received well over 20,000 infusions of MSC,  both  autogeneic and 
allogeneic, and  there  have been  no episodes  of rejection.
1.3.6.5 Ectopic Tissue Formation
MSCs have  the capability to differentiate into a number of mesodermal tissues  and, possibly, tissues 
derived from other germ  layers.  Ectopic calcification and/or ossification were observed with  direct  injection of  
MSCs into infarcted  mouse heart74.  Ectopic  tissue formation has not been reported in  any human  studies.   
Despite being  specifically sought, ectopic tissue formation was not  seen in  3+ years  of follow-up in  7 subjects 
who underwent  MSC/HSC co-infusion62.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 26 of 731.3.6.6 Graft vs. Host Disease
GVHD should not be an  issue  with removal  of lymphocytes during  culture  expansion. In addition, 
allogeneic MSCs are  now standard of care  in pediatric patients requiring allogeneic bone marrow  
transplantations for  the prevention of GVHD.
1.3.7 Experience in  Isolation and Culture  Expansion of Mesenchymal Stem Cells
MSCs have  been isolated  and cultured in large  numbers in  the Cellular Therapy Laboratory of the Case 
Western Reserve University Center  for Stem Cell and  Regenerative Medicine under several INDs, including  
IND 11176 and IND  13917.   MSCs are isolated from a  BM aspirate  (50-100 ml using a  brisk pull) and culture-
expanded according  to procedures outlined in existing SOPs.  Culture  expanded  MSCs are tested for 
morphology, surface antigen expression,  potential microbiological contamination, and viability prior to release 
for infusion.  
Human MSCs have been generated from  approximately  3000 individual donor marrows over the past 25 
years at Case Western  Reserve University.  Typically, >250  x 106 MSCs can be generated from a  20-mL BM 
aspirate.  Human MSCs propagated in culture  are ≥95% pure as judged by reactivity to  MSC-specific 
monoclonal antibodies to CD105 and CD7383.  Culture  conditions  are specific  for growth of MSCs.  Adherent 
CD14+ or CD45+ hematopoietic  cells  are eliminated from  the culture after the first passage.  The techniques for 
propagating MSCs in tissue culture have been  highly successful, and cultures  remain  free of contaminating 
bacteria, fungus, mycoplasma or endotoxin  for at least  7 weeks (personal communication  J. Reese).
1.3.8 Cystic  Fibrosis Clinical Trial Experience at Rainbow Babies and Children’s Hospital
The Cystic  Fibrosis Clinical Research Center  located at  Rainbow Babies and Children’s Hospitals/Case  
Western Reserve University has extensive experience in  conducting  clinical  trials in  CF.  We have a long 
standing tradition  of research since  the Clinical Care Center’s inception over 50 years  ago.  Our Research 
Center was  one of the  original 7 Centers  of the Cystic  Fibrosis Foundation’s  Therapeutics Development 
Network, which  was established  in 1998.  We  have  participated in  nearly every clinical trial in  CF since that  
time. This Center  consistently has 30 or more  active  CF clinical research trials approved by the Institutional  
Review Board  (IRB).  Dr. Erica Roesch is the PI on this  clinical trial.  Dr. Roesch has been site PI on 4 clinical 
trials and site  Co-I on several other CF clinical trials since  joining  the CF  clinical  research  team over two years  
ago. Dr.  Roesch  will be assisted in this study by Dr. Ross  Myers and  Dr. Michael Konstan, both  of whom are 
experienced clinical  investigators. Dr. Konstan has published well over 100 peer reviewed manuscripts on CF 
clinical trials and  served as  site PI, site Co-I and Lead PI  on dozens of multicenter clinical trials  in CF. He has  
been instrumental in bringing several approved therapies for CF to market. In addition, Dr. James  Chmiel,  the 
previous PI  on this study, will serve as a  collaborator  from  his new institution.  This  Center is well-known for its 
excellence in clinical  research.   
2STUDY RATIONALE
In CF, the current estimated median age  of survival is  37 years84.  The leading  cause of shortened 
survival is  progressive lung  disease85. Major accomplishments have been  made  in developing small molecule  
correctors and  potentiators of CFTR,  but a cure remains elusive.   One  would predict that  intervening at the gene  
level with gene replacement therapy  or at the protein level with CFTR potentiators and/or correctors early in 
that pathophysiologic  cascade would result in improvements in downstream consequences, particularly  at the 
level of  the exuberant inflammatory response.  However,  recent  clinical trials with drugs  to improve CFTR  
function have  not produced measurable improvement in  airway inflammation despite improving  lung function 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 27 of 73and, at times, decreasing bacterial  infection86.  As the pursuit  for a  cure  continues,  new  and innovative 
therapeutic approaches are  desperately needed  to provide improved resolution  of the on-going damaging 
infection and inflammation  in the  CF lung87. 
Bone marrow-derived hMSCs, which  may ameliorate the consequences  of CF, possess several 
advantageous properties 88.  First, hMSCs can be isolated  from  non-CF  subjects by simple  bone marrow 
aspiration and  expanded in culture up to a billion fold  within 8 weeks.  This allows for potential wide-spread use  
of this therapy  if hMSCs are  found to be safe  and effective.  Second,  hMSCs  can differentiate into gut  and 
respiratory epithelial cells89,90, suggesting not just pulmonary, but  systemic  benefit.  Third, hMSCs are 
immunoevasive because they lack  major histocompatibility complex and co-stimulatory cell-surface antigens. 
Thus infusion of hMSCs  from other humans is well tolerated91. Humans have received well  over  20,000 
infusions of  hMSCs,  both autogeneic and allogeneic,  and there have been no episodes of tissue rejection or  
adverse reactions. Fourth, hMSCs have  both anti-inflammatory and  antimicrobial properties 88.  Our preclinical  
data suggest that  hMSCs decrease bacterial  burden  and inflammation in a  murine model of CF lung infection,  
and we  have been able to demonstrate in vitro that the  hMSCs have the capacity to enhance the effectiveness of  
antibiotics often utilized to treat  the infections  associated with CF19.  Fifth, our studies also  showed the unique 
capacity of  the MSCs  to cross species  from humans into  mice to demonstrate a beneficial effect without any 
major adverse  effect.
The overall goal of  this project  is to determine the safety and tolerability of hMSCs and to  explore 
efficacy endpoints  for a subsequent clinical  trial.    Baseline studies  for inflammatory markers in  blood  and 
sputum will be determined.  This will be  followed by a  single infusion of hMSCs. These  studies will be 
repeated at 7 and  28 days  and compared  to Baseline values (with-in  subject  comparison). If hMSC infusion is  
determined to  be safe in this study, it could then be advanced to  a Phase II double-blind,  placebo-controlled  
clinical trial.  If successful, hMSC  therapy eventually could become part  of a patient’s therapeutic  maintenance 
regimen. Such alternatives are  sorely needed, because the data show that  anti-inflammatory therapy is likely to 
ameliorate disease and  prolong  life, yet it is not applied to  most  patients due  to concerns about adverse  effects. 
2.1 Risk  / Benefit Assessment
While hMSCs are highly promising  and supported by pre-clinical studies,  they must  be safe. The current  
data support their safety. While our proposal is the first for hMSCs  in CF, there have been  several other studies 
suggesting hMSCs  are safe  in COPD,  idiopathic pulmonary  fibrosis, bronchopulmonary  dysplasia, acute 
respiratory distress  syndrome, as well as many non-pulmonary diseases23 ,91. There are 500 completed or on-
going clinical  trials  using  hMSCs, and a  recent meta-analysis did  not reveal  any association between hMSC 
treatment and the  development of acute  infusion-related toxicity, organ system  complications, infection 
(important for  CF subjects), death, or malignancy 22,92.  
Our multidisciplinary team has extensive experience in  isolating and expanding hMSCs.  We are  
fortunate to collaborate  with  world-renown investigators from the NCRM, a  multi-institutional, state-sponsored 
organization composed  of investigators and clinicians from  University Hospitals Cleveland Medical Center  and 
Case Western Reserve University. Our  collaborators have a  30 year history of adult  stem cell  research including  
the first  in man studies of hMSCs and experience with studies similar to  ours in  patients with other chronic 
inflammatory diseases93,94. We  will be utilizing the NCRM Cellular Therapies Integrated Service to help  with 
the preparation  of cells  and scale  up from research to clinical operations.
Infusion with allogeneic hMSCs has been  shown  to be safe in follow-up  periods lasting  up to several 
years in patients  with pulmonary disease and other inflammatory  disorders including Crohn’s disease,  graft-vs.-
host disease,  multiple  sclerosis, and type 1 diabetes20. Up to 1 x 107 cells/kg have been  infused  safely.   There 
have not been any  issues  with infusion-related  toxicities  or tumor development. Autopsy  studies  reveal limited  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 28 of 73residual MSCs up to 18 months after administration21.  A meta-analysis of clinical trials  of MSC infusions to  
evaluate safety identified 1012  participants  with varying clinical conditions22.  The authors did  not detect  any 
association between  hMSC infusion and acute infusion-related toxicities, organ system complications,  infection, 
death or  malignancy. However there was a significant association  between MSCs and  transient  fever22.  
A significant concern in CF  patients  receiving potent anti-inflammatory drugs is the increased risk of 
pulmonary exacerbations.  Weiss and  colleagues performed a placebo-controlled, randomized trial  of 
mesenchymal stem cells in COPD  where 31 subjects received four  monthly stem cell infusions and there was  no 
difference in hospitalizations  for COPD  exacerbations during the study (six in the MSC group and five in the  
placebo group)23.  A recent  meta-analysis  did not detect  an association between MSC treatment and the 
development of infection22.  Preliminary data  in CF animals  suggest improvement in  infection related outcomes, 
not worsening18,19.  In our studies  of CF  mice infected with  P. aeruginosa, there was a  decrease in  the bacterial  
burden in the  animals that received hMSC infusions (Figure  1).  No secondary spread or infectious 
complications were  noted.  
Another potential concern  is the possible increased  risk of cancer.  Again, this has not  been detected in 
clinical trials22,24. However, the potential for  malignant transformation  would not be unexpected given some  of 
the biologic similarities  between stem cells and  cancer  cells.   The risk of tumorigenesis is likely to be  an 
extremely uncommon event with current culture conditions  where cells are harvested for  therapy  well  before  the 
cultures reach  senescence20.  Another  potential risk could result if hMSCs engrafted for long periods of time  
leading to ectopic  tissue formation  and increased  risk of malignant transformation.  Autopsy studies did  not 
detect hMSCs in follow-up studies.  It appears  that hMSCs  work  through  a “hit and run”  mechanism21.  Despite 
these theoretical concerns, there  have  been no reports of de  novo tumor formation complicating  MSC  infusion 
in humans22,24.  Nevertheless,  in our  protocol, cells will be  passaged the minimum number of times to obtain  
sufficient cell yield  to lessen potential  for cytogenetic abnormalities, and  any potential CF subjects  with a 
history of  invasive  cancer requiring systemic therapy will be  excluded from the study.
3STUDY OBJECTIVES
3.1 Primary Objective
To evaluate the infusion-related safety  and tolerability of a single allogeneic hMSC infusion  in adults 
with CF.  
3.2 Secondary Objectives
To explore  preliminary evidence for the  potential  efficacy of hMSCs as a new therapeutic to treat CF 
pulmonary infection  and inflammation  as measured by
oChange in sputum inflammatory markers
oChange in serum  inflammatory markers
To compare allogeneic hMSCs to autologous hMSCs  in a preclinical model.  The potential efficacy  of 
MSCs obtained  from CF subjects who agree to undergo the optional  bone  marrow aspiration will be evaluated  
in validated animal  models. 
3.3 Implications for Future Studies
This study  is designed to address the  safety  and tolerability of a  single hMSC infusion in subjects with  
CF.  While  in the  background section we  have  focused primarily on the impact of MSCs on the pulmonary 
inflammatory response, hMSCs have  potential  to impact multiple other aspects of  CF lung pathophysiology.  
MSCs also likely  possess  antibacterial properties.  In our mouse models, hMSCs in combination  with  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 29 of 73gentamicin was more  efficient  in clearing bacteria than either therapy alone.  This  suggests  the potential to  use 
MSCs to enhance antibiotic regimens for acute pulmonary exacerbations in  CF.  In addition, because study 
subjects will be receiving hMSCs that do not possess a  mutation in cftr, it is possible that  hMSC infusion  will 
provide a form of gene therapy.  In future Phase III studies, we will evaluate the effects of hMSC infusion  on 
outcome measures related  to infection, inflammation  and CFTR correction.
4 STUDY  DESIGN
4.1 Study Overview
Overview of Study Desig35Tn35T  A prospective,  single-center, single-dose, dose-escalation, open-label interventional 
study to  evaluate  the safety and tolerability  of allogeneic hMSCs in  15 clinically  stable  adult subjects with  CF. 
Because the subject’s own cells will contain two CFTR mutations, allogeneic hMSC infusion  is being employed 
in this  study.   Screening  data will be reviewed to determine subject eligibility.  Subjects who  meet all inclusion 
criteria and none of the  exclusion criteria  will be entered into the study. The Tables in  Appendix II review the 
schedule of  study visits.   After a two to six week screening period, subjects will have the  Baseline visit (Days 1-
2) where  they will undergo  a single infusion of up to 5 x 106 allogeneic  hMSCs/kg.  The CCC  and NCRM at 
Case Western Reserve University have  a long-standing  approach to  identifying, screening and using donors to  
provide hMSCs.   Donors  are screened per FDA guidelines for cells and tissues (21 CFR 1271).  The FDA  
guidelines are similar to those used for  blood donation by Red Cross.   The  allogeneic hMSCs used in this study 
will come from  one or two healthy  donors who have  been well-characterized by the CCC and whose  sera test 
negative for CMV antibodies. Healthy donors will be followed by the PI  or designee for any  procedure-related 
AEs. Infusions will be  performed in the Dahms Clinical Research Unit  at University  Hospitals  Cleveland 
Medical Center. Study participants will be monitored for the development  of infusion-related  toxicities  for 24 
hours.  Subjects will have subsequent study visits  on Days 7, 14, 28, Months  3 and  6 and telephone calls  on 
Days 4  (or 5), 21, 56 and Month 12.  Subject safety and tolerability of the single dose of  hMSCs will be  
evaluated at the study visits  by reviewing subject  diaries, interval  histories, and subject questionnaires, 
performing physical examinations and spirometry, and obtaining safety laboratories.  In addition to  infusion 
related toxicities, special  focus will also be placed upon  detecting  pulmonary  exacerbations since an anti-
inflammatory therapy  theoretically could suppress the immune system to  the point where it leads to  increased 
infectious complications.  Appendix I lists the criteria for a pulmonary  exacerbation.    This study will also 
explore efficacy endpoints that previously have  been  shown  to be key  regulators in CF and/or hMSCs:  Serum 
inflammatory biomarkers   (calprotectin, MPO, GM-CSF, IL-1β, IL-6, IL8,  IL-17, and TNF-), and sputum 
inflammatory biomarkers  (white cell counts with differentials, IL-1β, IL-6, IL-8, IL-10,  IL-17, GM-CSF, MIP-
3, TNF-, and active proteases  including neutrophil elastase,  R1R-anti-trypsin, and MMP-9).  These  studies 
will be repeated on Days 7 and 28 and  compared  to Baseline values (with-in  subject  comparison).  All subject 
samples will be archived for future studies to explore  the impact  on the  microbiome and for future translational 
projects.  Finally, an  optional diagnostic bone marrow  exam  will be performed between screening and Day 1 on 
CF subjects  willing to  undergo the procedure,  banked, and  used for  future translational studies. 
The following treatment regimens will be  used:
Experimental treatment hMSCs at the  following doses:  1 x 106, 3 x 106 or 5 x 106 hMSCs/kg body 
weight
All subjects who begin  an infusion  of the investigational product will be considered evaluable  for safety 
and efficacy analyses.  Incidence of AEs will be  monitored during the trial. 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 30 of 73Safety assessments  will be  based on the incidence  of AEs including protocol defined pulmonary  
exacerbations and  changes  in lung function, sputum microbiology, safety labs,  subject questionnaire, and 
physical examination. An Acute  Illness Visit will be arranged for any subject who experiences  any abrupt 
change in baseline  clinical  status, between Visit 2 and  Visit  5 (the 28 days following infusion) that  in the 
estimation of  an investigator, research coordinator, other  health  care provider or the subject necessitates an  in-
person office visit.
Total duration of  subject participation in the  study will be  approximately  13 months.  Long-term post-
treatment follow-up will continue for 12 months after  the infusion  of the investigational  product for each 
subject. Data  on subject survival and  on the occurrence of new health problems  will be  collected from all 
subjects who receive  the investigational  product  infusion. The information will be gathered  during a  study visit, 
a routine clinic visit  or via  telephone. These  data will be  collected in  the source documents (e.g., subject  
medical record)  and transcribed into an electronic  CRF. Any  unsuccessful efforts to  contact the subject (e.g.,  
dates of unanswered  phone calls,  failure to show for a clinic visit, etc.) will be  documented in  the subject’s 
source documents.   
Total duration of  conducting the  study  is expected  to be approximately 24 months.
5CRITERIA FOR EVALUATION
5.1 Primary Endpoint
The primary outcome will be  the safety and  tolerability of a single infusion  of allogeneic  hMSCs. Study 
participants will  be monitored for  potential  dose limiting toxicities.  The dose limiting toxicity  (DLT) definition 
consists of the emergence of infusion-related allergic AEs as well as regimen  related toxicities. For this  study, a 
DLT will be considered  for the occurrence in the  first 24 hours  after hMSC infusion  of a grade ≥ 3 infusion-
related allergic toxicities, which include rash, flushing,  urticaria, dyspnea, fever >40°C (>104.0°F) as scored 
according to  the National Cancer Institute  (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. Finally, the  CTCAE  will be  used to assess and grade AE severity, including laboratory 
abnormalities judged to be clinically significant.  In addition to infusion  related toxicities,  special focus will also 
be placed upon detecting pulmonary exacerbations since anti-inflammatory therapies theoretically  could 
suppress the immune system  to the  point where  it leads to  increased infectious complications.  Appendix  I lists  
the criteria for defining  a pulmonary exacerbation treated with antibiotics.  All AEs encountered  during  the 
study period will be  captured and graded.    
In addition  to DLT,  safety and tolerability  of a single infusion  of allogeneic mesenchymal stem cells  will 
also be  determined  by 
Incidence  and severity of AEs 
Number of pulmonary exacerbations (modified  Fuch’s definition95)
Diary reports (Cystic Fibrosis Respiratory  Symptom Diary)
Changes in subject reported symptoms as captured by the Respiratory and Systemic  Symptoms 
Questionnaire from  Baseline (Visit 2) Day 1 to Baseline (Visit  2) Day 2, Visits 3, 4, 5, 6, and 7 and at 
times when a  pulmonary exacerbation is being considered. 
Changes in physical  examination 
Changes in vital  signs including oxygen  saturation checked  throughout the infusion
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 31 of 73Changes in spirometry  (FEVR 1R %, FEVR 1R (Liters),  FEFR 25-75R) determined  30 minutes, 4 hours and 24 hours  
after completion  of infusion and from Baseline  (Visit 2) Day 1 to Baseline (Visit  2) Day  2, Visits  3, 4, 5, 
6 and 7.
Change in sputum  quantitative microbiology  (change in bacterial colony forming units  between Baseline 
Day 1 and Day 7 and Day  28)
Changes in hematology,  comprehensive chemistry, erythrocyte sedimentation rate (ESR), high-sensitivity 
C-reactive proteine (hs-CRP), and urinalysis results
5.2 Secondary Endpoints
Since this is a phase I study,  the primary  focus  is on safety.  However, in a  15 subject dose-escalation 
study, we will also explore potential  efficacy endpoints.  Secondary outcomes include:  changes in  biomarkers  
of inflammation in blood  (calprotectin, MPO, GM-CSF, IL-1β, IL-6, IL8, IL-17, and  TNF- ) between Baseline 
Day 1 and Day  7 and Day  28, and changes  in biomarkers of inflammation in  sputum (white cell  counts  with 
differentials, IL-1β, IL-6, IL-8, IL-10, IL-17,  GM-CSF, MIP-3 , TNF-, and active proteases  including 
neutrophil elastase, R 1R-anti-trypsin, and MMP-9) between  Baseline Day 1 and Day 7 and  Day  28.  
6SUBJECT  SELECTION
6.1 Study Population
Study Population: CF subjects will be recruited  from the LeRoy W. Matthews Cystic Fibrosis Center 
located at Rainbow Babies and  Children’s Hospital in Cleveland, OH.  Our  Center provides care for over 200  
adult patients with CF.  Given the  wide interest in hMSCs  in CF, we do not  anticipate any issues recruiting 15 
subjects for this study  from our  Center. However, should  recruitment  lag behind projected timelines, we could 
recruit potential  study subjects from  nearby  CF Centers in  Akron,  OH, Ann Arbor,  MI, Buffalo, NY, Columbus,  
OH, Pittsburgh,  PA, and Toledo, OH.  Subjects will be studied for up to 13 months.  Screening will be between  
10 and 42 days.  Study treatment will be  Day 1 with a  12-month follow-up.   We  anticipate  15 months  to recruit 
subjects (due  to the  3+3 safety  study design, the last subject in a  given cohort  must complete Visit  5 before the  
first subject  in the  next cohort  can be enrolled). Subjects  who fail screening or who  withdraw prior to  
completing Visit 5 will  be replaced.  Subjects with a diagnosis of CF  who meet the inclusion  and exclusion  
criteria will be  eligible for participation  in this  study.  Subjects who  fail screening  may be  re-screened one 
additional time.  
6.2 Inclusion Criteria
1.Male or female 18 years of age and above
2.Confirmed diagnosis of CF as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 
or more of the following criteria:
a.Sweat chloride equal to or  greater than 60 mEq/L by quantitative  pilocarpine  iontophoresis test 
(QPIT) 
b.2 well-characterized, disease causing  mutations in the CFTR gene 
3.Clinically stable with no significant changes in health status within 2 weeks  prior  to screening 
4.FEVR 1 R≥ 40% predicted  for age based on the  global lung  function initiative equations at the screening visit  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 32 of 735.Weight ≥ 40 kg at the screening visit
6.Able to perform repeatable, consistent efforts in pulmonary function testing
7.Written informed consent  obtained from the subject
6.3 Exclusion  Criteria
1.Use of an investigational agent  within the 4-week period prior to  Visit 1 (Day -42 to  -10)
2.Chronic daily (>10 mg) or alternate  daily (>20 mg on alternate days) use of systemic corticosteroids within 
the 4 weeks prior to Visit 1 (Day  -42 to -10) or initiation of any dosage of systemic  corticosteroids within 72 
hours prior to  Visit  2 (Day 1) 
3.Use of hydroxychloroquine or immunosuppressants 
4.Initiation of a new antibiotic (oral,  IV, and/or  inhaled) that is not part of the subject’s maintenance regimen 
for treatment of acute  respiratory symptoms  within 2 weeks prior to screening through Visit  2 (Day 1)
5.Initiation of any new chronic therapy (e.g.,  Pulmozyme®, hypertonic saline, Kalydeco®,  Orkambi®, high-
dose ibuprofen  azithromycin, TOBI®, Cayston®, nebulized colistiin,  bronchodilators, inhaled  corticosteroids, 
etc.) within 4 weeks prior  to screening
6.Active treatment for  non-tuberculous Mycobacteria 
7.History of a sputum culture positive for a Burkholderia cepacia complex organism in the previous  12 months 
8.Current tobacco smoker
9.Oxygen saturation <  92% on room air  at Visit 1 (Day -42 to -10)
10.History of pulmonary  hypertension
11.SGOT (ALT) or SGPT (AST) > 2.5 times the upper limit of normal at screening,  documented biliary cirrhosis, 
or portal hypertension 
12.Total  bilirubin  concentration >1.2 mg/dL at  screening
13.Creatinine  > 1.8 mg/dL at screening
14.Pregnant, breastfeeding,  or unwilling to practice  birth control between Visit  2 (Day  1) and Telephone Call 3 (Day 
56) (acceptable forms of contraception:  abstinence, hormonal birth control, intrauterine device, or barrier 
method plus a  spermicidal agent), unless surgically  sterilized  or postmenopausal
15.Screening  hematology with white blood cell count < 4.5 x 109 cells/L,  hematocrit < 30%, and platelets < 150 
x 109 platelets/L  
16.History of invasive  cancer requiring  systemic therapy 
17.History of organ transplantation
18.Currently listed for  lung transplantation  or having potential to  be listed for lung  transplantation in the 
succeeding 12 calendar months from screening
19.Subject unlikely to complete the study as determined by the Investigator
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 33 of 737CONCURRENT MEDICATIONS
All subjects should be  maintained on the same  medications from  screening through Visit 5 (Day  28), as 
medically feasible, with no  introduction  of new chronic  therapies.  Medication history  will be collected for all  
drugs for  the 30 days prior to screening. If any  changes  in concomitant medications are required due to AEs (i.e.  
illness, laboratory  abnormalities, surgical procedures, etc.),  the reason(s) for the change(s) must be documented.  
Subjects who require  treatment for a pulmonary  exacerbation during  the course of the trial  will remain in  the 
study. 
Subjects who have routinely taken  more  than 10 mg/day (or >20 mg  on alternate  days) of prednisone or 
other systemic corticosteroids 4 weeks  prior to Visit 1  (Day  -42 to  -10) or who  have taken these medications  as 
needed within  72 hours prior to Visit 1 or 2 will be  excluded  from participation.   Subjects  may be  re-screened 
once. For  those subjects taking alternate  month TOBI® or Cayston® therapy, on/off cycles  must  be timed  such 
that a subject is at the same  phase  of a cycle at Visits 2, 3, 4, and 5.
7.1 Allowed
Except as  noted in the prohibited  medications  section below or in  the exclusion  criteria described above, 
all usual  CF medications and treatments  are allowed.  A  stable therapeutic regimen  (including physiotherapy)  
between screening and Visit 5 (Day 28) is the goal.  Ongoing chronic treatment (> 4 weeks prior to  screening) 
with Pulmozyme®, Cayston®, TOBI®, nebulized colistin,  Kalydeco®, Orkambi®, high-dose  ibuprofen,  
hypertonic saline, azithromycin,  systemic  or inhaled corticosteroids, short and long  acting bronchodilators  and 
airway clearance is  allowed.  Unless otherwise  medically  indicated,  subjects not using these therapies  should  
not be started  on them from screening through  Visit  5 (Day 28)  and subjects that have been using them 
chronically should be  encouraged to continue them through Visit 5 (Day  28). Limited use of over-the-counter 
anti-inflammatory drugs (acetaminophen, aspirin,  ibuprofen, or naproxen)  from screening through Visit 5 (Day  
28) is acceptable.
7.2 Prohibited
Intravenous  antibiotics from 14 days prior  to the screening visit  through Visit 2 (Day  1)
Newly prescribed  oral or inhaled antibiotics prescribed for acute  symptoms from 14 days prior  to the 
screening visit through Visit 2 (Day 1)
Systemic corticosteroids  prescribed  for an acute issue or for chronic therapy if  the dose exceeds  a 
prednisone equivalent of  10 mg every day or 20 mg on alternate days (maximum allowable dose for 
chronic systemic corticosteroids  is 20 mg of   prednisone or its  equivalent over a  two day period) 
from screening through Visit 5 (Day  28)
Hydroxychloroquine from screening through Visit 5 (Day 28)
Other immunosuppressants from screening through Visit 5 (Day  28)
The use of an investigational agent within 4 weeks prior to  Visit  1 (Day -42 to  -10)
8STUDY TREATMENTS
8.1 Method of Assigning Subjects to Treatment  Groups
In this Phase I  open-label  study, there is no placebo group.  All subjects  will receive a  single  infusion of 
hMSCs.  15 eligible  subjects will be recruited  from the adult  CF Center located at Rainbow  Babies and 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 34 of 73Children’s Hospital  and will receive  a single  dose of one of the following doses of hMSCs: 1 x 106, 3 x 106 or 5 
x 106 hMSCs/kg  body weight. A traditional 3+3 design will be  utilized  (Figure  4). If a maximum tolerated  dose  
(MTD) is  identified  among the 3 doses, the next  3 subjects enrolled will receive  the identified MTD.  If there are 
no DLTs  or one DLT, the next 3 subjects  enrolled will receive same  dose. If there are two or more DLTs, the 
next lower  dose will  be used as the  MTD for the final 3 enrolled  study  subjects.
Figure 4. Study design for determining dose-limiting toxicity 
8.2 Blinding
Because this is an open-label,  safety  and tolerability  study in which  all enrolled subjects  will receive hMSCs, 
this study is unblinded.
8.3 Test and Control Formulation
The biological product  (hMSCs) is manufactured  in the Case Western Reserve University  NCRM  
Cellular Therapy  Laboratory under GMP-compliant  regulations.  This laboratory is located on the campus of  
Case Western Reserve University/University Hospitals  Cleveland Medical Center.
Address:
WRB 6-303
2103 Cornell Road
Cleveland, Ohio 44106
(216) 368-1007
The cells obtained from  the donor(s) will be cryopreserved  at primary  culture.   There will be  no 
passages involved.   Only plated and adherent  cells will be  harvested.  This occurs at approximately 14 days.   
The number  of passages after thaw (prior to infusion) is dependent on the  target dose (recipient receives  a dose  
based upon  weight).  For  most  participants,  we will likely reach  our target dose after 2 passages and no greater  
than 3 passages.   This translates into approximately  14 days. 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 35 of 73The final hMSC formulation  is a fresh cell  suspension of 4 x 106 cells/ml with ≥70%  viability in Plasma-
Lyte A  + 2.5% HSA.   This  product  is distributed in a syringe  for immediate  infusion.
8.3.1 Packaging and Labeling
The biologic product is packaged and  labeled  for infusion according to FDA  guidelines by Cell 
Processing Technologists  employed by the CWRU NCRM Cellular Therapy Lab.  Blinding  is not  applicable  to 
this study. The infusion product  will be  labeled  as follows:
Investigational  Drug (Study Name or #)
FOR INFUSION
Subject  Unique Identifier:
Cellular  Therapy Laboratory
WRB 6-303
2103 Cornell Road
Cleveland, Ohio 44106 (216) 368-1007
Date:  Total Cells:
Volume:  X ml  Expiration:  dd/mm/yyyy  Time hh:mm
CAUTION:  NEW DRUG-LIMITED BY  FEDERAL LAW TO INVESTIGATIONAL USE
8.3.2 Handling/Dispensing
Human MSCs will be dispensed directly from manufacturing personnel to clinical personnel per 
conditions noted  in the  IND application  and the clinical protocol.   Chain  of custody  will be tracked  in writing 
and documents filed in both the subject  study  record  and manufacturing record.
8.3.3 Dosage/Dosage Regimen
The first cohort of 3 subjects enrolled  will receive  a single  infusion  of 1 x 106 hMSCs/kg body weight, 
The second  cohort of  three subjects enrolled  will receive a  single infusion  of 3 x 106 hMSCs/kg, and  the third 
cohort of three subjects  enrolled will receive a single infusion of 5 x 106 hMSCs/kg.  The first  subject in  the 
subsequent cohort will not be enrolled until the  last subject  in the preceding cohort has completed Visit  5 (Day 
28).  There  will be  a minimum of 1 week  between  the dosing of each study subject in  the first three cohorts.   
The final six  subjects will receive  a single infusion of  5 x 106 hMSCs/kg if that  dose was well tolerated.  If the  
highest dose  was not well  tolerated, then the final  six subjects will receive the maximum tolerated dose (either 1 
x 106 or 3 x 106 hMSCs/kg body weight).
Table 1: hMSC dose cohorts
Cohort 1 1 x 106 hMSCs/kg 3 subjects
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 36 of 73Cohort 2 3 x 106 hMSCs/kg 3 subjects
Cohort 3 5 x 106 hMSCs/kg 3 subjects
Cohort 4 MTD 6 subjects
8.3.4 Administration Instructions 
The person  infusing  the cells should wear sterile  gloves.  
Fresh hMSC will be  administered as  follows:
hMSCs are infused  through  a peripheral  venous catheter by directly connecting the syringe of 
cells to  the IV tubing via Y-connector.
1.Start infusing IV fluids (normal  saline) at the  maximal rate  (250 ml/hr.).
2.Clean  the port of  the Y-connector as per hospital protocol.
3.Remove needle from  syringe containing the hMSCs.
4.Attach the  syringe with hMSCs directly to the in-line Y-connector.
5.Manually clamp the IV tubing leading back to the bag  of saline behind the syringe by 
pinching the tubing between two fingers.
6.Administer a  small aliquot (2-3 ml) of the  cells from the syringe  by slow  IV push.
7.Release the IV tubing and allow  the normal saline to  flush the line for 1-2 minutes.
8.Repeat steps 5 through 7 until all the cells have been infused, completing the infusion over 10-15 minutes.
9.The first post cell infusion rinse of the syringe  must now be  performed.   
10.Manually clamp the IV tubing between the  syringe  and the study participant by bending 
the tubing and  pinching  it between  two fingers to draw saline fluid into the syringe,  
complete filling the syringe.
11.Release the IV tubing leading  between the syringe and the study participant.
12.Manually clamp the IV tubing between the  bag of saline  and the syringe by bending the 
tubing and pinching  it between two fingers.
13.Administer an  aliquot  (3-5 ml) of fluid from  the syringe by IV push.
14.Release the IV tubing and allow  the normal saline to  flush the line for 30 seconds to 1 
minute.
15.Repeat steps 12 through 14 until the syringe is empty.  Completing  the saline rinse should  
take approximately 2 minutes.
16.Perform a  second post cell infusion rinse  of the syringe.
17.Repeat steps 10 through 15.
18.Remove the syringe from the Y-connector  port.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 37 of 7319.Administer normal  saline through the running IV  at a rate  of 250 ml/hr. for 4 hours while 
the study participant  is being monitored  after the infusion.
20.Document the  infusion in a procedure note in the electronic  medical record (EMR).
Infusion reactions are documented in the  subject’s  study chart and the principal investigator  is notified  
in the event of severe reactions.
An infusion side-effect checklist is provided  to the subject’s nurse (a modified version of the standard 
form used by University  Hospitals  Cleveland Medical Center Seidman Cancer Center).
Side effects are monitored  for 24 hours after the completion of the  infusion.
8.4 Supply  of Investigational  Product at the Site
The cell  product will be  expanded to the clinical dose in  culture  upon receipt of a physician  
investigator’s order.  Duration  of culture  expansion is approximately 15-20 days after which cells  will be 
infused once release  tests are complete.
8.4.1 Storage
Stock vials of primary culture hMSCs  will be secured in liquid nitrogen vapor  phase until  indicated for 
expansion per physician investigator’s order.   Liquid nitrogen freezers are  remote alarm monitored 24/7. The 
expanded hMSCs for infusion will be used fresh  without further frozen storage.
8.5 Investigational Product Accountability
An accurate and current  accounting of the  amount of hMSCs administered  to each subject will be  
maintained by  research  staff.  Research staff  will document the total dosage of hMSCs administered  to each 
subject.  If  the infusion is  stopped  for any reason,  including  adverse  reaction or technical  difficulty,  research 
staff will  determine how much of the infusion the  subject  received  and record the administered  dose in  the study  
records. 
8.6 Measures of Treatment Compliance
In this Phase I  study,  subjects will receive a single infusion of hMSCs that will be administered by 
research staff  in the  Dahms  Clinical  Research Unit of  University Hospitals Cleveland Medical Center.  
Therefore we do not anticipate  that there  will be  any issues  with  treatment compliance during this study. 
9STUDY PROCEDURES AND GUIDELINES
A Schedule of Events representing the  required testing procedures to be performed for the duration of 
the study  is outlined  in Appendix II.
Prior to conducting any  study-related activities,  written informed consent and the Health  Insurance 
Portability and  Accountability Act (HIPAA) authorization  must be signed and  dated by the subject.
9.1 Clinical Assessments
9.1.1 Concomitant Medications
All concomitant  medications and  concurrent therapies will be documented at all study visits including an 
Acute Illness/Early Termination Visit when applicable.  Dose,  route, unit frequency  of administration,  and 
indication for  administration and dates  of medication will be  captured for the 30 days prior to  screening.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 38 of 739.1.2 Demographics 
Demographic information (date  of birth, gender,  race) will be recorded at Screening.
9.1.3 Medical History  
Relevant medical  history, including  history of  current  disease,  cftr genotype  analysis  results, sweat 
chloride results, sputum  microbiology, spirometry results, other pertinent respiratory history, and  information  
regarding underlying diseases will be recorded  at the screening visit (Visit  1).  An  interval history  will be 
obtained at all other visits. 
In the event of a  pregnancy between Visit 2 (Day 1) and Telephone Call 3 (Day 56), medical  information  
pertaining to the  pregnancy  will be collected  through the birth of the child or the termination of the pregnancy.
9.1.4 Physical Examination
A complete physical examination will be performed by a physician (either the investigator or a  sub-
investigator) at  Visits  1, 2 and 5 and at an  Acute Illness/Early Termination Visit.  Qualified staff (MD/DO, NP,  
RN, PA) may complete  the abbreviated physical exam at all  other visits.  The  physical  exam also includes  
height (at  screening  only) and weight.  The  complete physical  examination consists of general, HEENT, 
neck/thyroid, lymph nodes,  cardiovascular system, chest/lung,  abdomen, extremities, skin, musculoskeletal,  
nervous system,  mental  status,  and other. An abbreviated exam will consist of HEENT, cardiovascular system, 
chest/lung, abdomen, extremities, skin,  and other.  New abnormal physical exam findings  must  be documented  
and will be followed by a physician or  other qualified staff  at the next scheduled visit.
9.1.5 Vital Signs
Body temperature, blood pressure, pulse and  respirations will be performed after resting for 5 minutes  at 
all study  visits.
9.1.6 Oximetry
Oximetry will  be measured on room air with the  subject  at rest at all study visits.
9.1.7 Spirometry
Spirometry will be  performed at all study visits and in accordance with  the current American Thoracic 
Society recommendations  for the performance and interpretation of tests. Spirometry will be obtained 
approximately 2 hours prior to the start of the hMSC infusion  and 30 minutes,  4 hours  and 24 hours  after 
completion of  the infusion.  Subjects will perform spirometry as is customary for that  subject at clinical visits. If 
the subject typically does not take  albuterol prior  to spirometry, then he/she will not  take  albuterol prior to  
spirometry during the  study.   If the subject typically  takes  albuterol  prior to  spirometry,  they he/she  will take 
albuterol prior  to spirometry for  this study.  However there is an exception.  In any  subject in  which  it is 
anticipated that  he/she might not be able to produce  sputum spontaneously at any one of the study visits in  
which sputum will be  obtained, then those subjects will  undergo  sputum  induction at all visits regardless of  his 
or her  ability  to spontaneously  expectorate sputum at the current study visit. In these cases, those individuals 
will receive  three inhalations  of albuterol  sulfate  via metered  dose inhaler prior to  all spirometric tests obtained 
during the study. Approximately  15 minutes after administering albuterol sulfate, pulmonary function  testing  
will be performed.   If a study subject is unable to produce sputum at the Baseline  Visit (Day 1), then sputum 
will not be obtained  at Visits 3 (Day 7) and 5 (Day  28).
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 39 of 739.1.8 Acquisition of Sputum
Sputum (approximately 1.3-2.0 grams)  will be obtained at Visit  2 (Day 1) prior to  the infusion of stem cells and 
on Visits 3 (Day 7)  and 5 (Day 28) via spontaneous  expectoration.  Sputum samples  will be  split according to 
priority for analyses.  The first aliquot will be sent to the microbiology  laboratory  at University Hospitals  
Cleveland Medical Center where  quantitative bacteriology will be  performed,  and the second aliquot will be 
processed and saved for  research studies. Sputum will be processed according to  the current standard  operating  
procedure (SOP)  developed by CF Foundation’s Therapeutics Development Network. Subjects unable to 
spontaneously expectorate sputum will undergo  sputum induction according to  the current  SOP developed by 
CF Foundation’s Therapeutics Development  Network.  If a  sputum  sample cannot  be produced, or the quantity 
of the sample is not sufficient for all  the tests to be performed, this  is not considered a deviation.
9.1.9 Intravenous  Infusion of hMSCs
Fresh MSCs are infused  at Visit  2 (Day  1) from a syringe into a venous catheter followed by a saline  
wash.  After the infusion of cells  is complete, 10-ml of a  normal  saline flush is given immediately and a  running 
IV of  normal  saline is maintained at 250 ml/hr for 4 hours. Subjects are monitored  for 24 hours  for infusion-
related toxicity.  Temperature,  blood pressure, heart rate, respiratory rate and  oxygen-saturation are  measured  
prior to infusion  and at 10 (±  5), 20 (± 5), 30 (± 5), 60  (± 15), and  90 (± 15) minutes  and 2 hours  (± 15 minutes)  
and 4 (±  15 minutes) hours  post-infusion and then every  4 (± 15 minutes) hours for  the remainder of the 24-hour  
observation period.  Any toxicity is treated at  the discretion of the managing physician, and  toxicities  are 
reported to the Principal Investigator, IRB, and  FDA  as appropriate.
MSC infusion has been very  well tolerated.  Although theoretically of concern, there have been no 
reported cases  of immunosuppression, autoimmunity,  cancer,  significant lung  damage, severe infection,  or 
clinically significant  ectopic tissue formation  attributable to  MSC infusion.  MSC infusion could cause  infection  
if the cells are contaminated.  Strict aseptic  technique  during  bone  marrow aspiration, culture,  thawing, and  
infusion and stringent microbiologic screening minimize this  risk.  Because of the immunosuppressive effects  
of MSCs,  recipients  potentially  are at increased risk for infection.  
9.1.10 Bone  Marrow Exam
Healthy volunteers who meet  screening criteria and  who  consent to  having their mesenchymal  stem cells 
subsequently infused  into study  subjects  with CF  will undergo  a bone marrow  examination according to SOPs  
developed by  the CCC well in advance  of the  infusion.   Either  a unilateral or bilateral  (depending  on the  yield 
of bone  marrow aspirate) posterior iliac crest  bone marrow aspiration will be performed using local anesthetics  
1% Xylocaine (approximately  10 ml intradermal and subcutaneous), preservative-free bupivacaine  0.25% 
(approximately 10-20 ml injected locally  to the site), morphine sulfate (approximately 2-6 mg by IV). 
Lorazepam (1  mg oral or IV) may be used if needed.  Approximately 60-80 ml of marrow is  pulled into syringes  
containing preservative-free heparin (400 units/25cc marrow) using a few brisk pulls.  Bone  marrow samples  
will be processed, and MSCs  will be prepared according to  CCC SOPs as previously described. 
If a subject  with CF consents to undergoing  the optional bone  marrow exam, screening procedures will 
be performed  at Visit  1 and a single bone  marrow aspiration of the  posterior iliac  crest  will be  performed  at 
Visit 1A  under  local  anesthetic 1% Xylocaine (approximately 10 ml intradermal and subcutaneous). For  CF 
subjects, the optional  bone marrow  aspiration procedure (Visit 1A)  must  be completed  at least 14 days before 
Day 1 (Visit 2). Preservative-free bupivacaine  0.25% (approximately 10-20 ml injected locally to  the site), 
morphine sulfate  (approximately  2-6 mg by IV),  and lorazepam (1 mg oral or IV) may be used if  needed.  
Approximately 5-20 ml of  marrow  is pulled into a  syringe  containing preservative-free heparin (400 units/25cc 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 40 of 73marrow) using a brisk pull.  MSCs isolated from  subjects  with CF will be evaluated in pre-clinical models to 
determine how  they  differ  from donor MSCs.  The CCC and NCRM at Case Western Reserve University have 
emerging cell therapy assay methods so that BM samples from subjects with  CF are able to  be archived and 
used at a later time  to more fully characterize  the CF defect.
The risks of a  bone marrow  aspiration include pain  at the time of the aspirate, which is common  but well 
controlled with adequate use of Xylocaine, bupivacaine and  morphine. Other risks include bleeding,  infection at  
the site  of the aspirate,  and occasional lightheadedness or fainting  due to a vasovagal reaction after  the 
procedure. Healthy volunteers  and subjects with CF, who undergo the optional bone  marrow examination, will  
be followed by  the study  PI or designee  for AEs related to  the procedure.
Inclusion Criteria for  Healthy Volunteer  Donors:
1) Male/female  age ≥ 18 years 
2) Able to understand  and sign ICF (a legally  authorized representative  will not be  permitted)
Inclusion Criteria for  CF Donors:
1) CF subject enrolled  in the main study and consented to  this optional procedure
Exclusion Criteria for  both Healthy Volunteer  Donors  and CF Donors:
1) Fever or current illness on the day of the  cell collection
2) Evidence  of communicable disease.
3) Any significant change in health status within  2 weeks prior  to cell collection that the PI/Sub-
Investigator deems relevant to exclude participation
4) Subject-reported history  of organ transplantation
5) Subject-reported history  of HIV, hepatitis B or C, or syphilis
6) For HV donors only, subject-reported known history  of being  diagnosed with  cystic fibrosis 
(CF) or being  a CF carrier (one copy of  CF gene  mutation)
7) Positive screening blood test result for  any infectious disease.  
8) For HV donors only, positive test result for  CMV or a CF gene mutation.
9) Pregnant, planning a pregnancy,  or breast-feeding at screening.
9.1.11 Adverse Events
Information regarding occurrence of AEs will be captured throughout the study from the time of consent 
until Telephone  Call 4 (Month  12 ±1). Duration  (start  and stop dates), severity/grade, outcome, treatment  and 
relation to investigational product  or study  procedures will be recorded in the CRF.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 41 of 739.2 Clinical Laboratory Measurements
9.2.1 Hematology
Blood (5 ml) will be  obtained at all study visits and sent to the clinical hematology laboratory at 
University Hospitals  Cleveland  Medical  Center  for a complete  blood count (hemoglobin, hematocrit,  red blood 
cell count, white blood cell  count,  white blood cell differential, and platelet count), ESR, and serum  hs-CRP 
determinations for  assessment of systemic  evidence  for infection  and/or  inflammation.
9.2.2 Blood Chemistry Profile
Blood (5 ml) will be  obtained at all study visits and sent to the clinical chemistry laboratory  at 
University Hospitals  Cleveland  Medical  Center  for determination of sodium,  potassium, chloride, bicarbonate, 
random glucose, BUN,  creatinine, aspartate aminotransferase (AST/SGOT), alanine aminotransferase 
(ALT/SGPT), alkaline phosphatase,  total  bilirubin, direct  bilirubin, albumin and LDH.   Because  vitamin  D may  
influence hMSC  function, a vitamin  D concentration  will be obtained at  Visit 2 and analyzed post hoc . 
9.2.3 Pregnancy Test
A pregnancy test will be  performed on female subjects who  are of childbearing  potential  prior  to their  
participation in  the study. A  serum  pregnancy  test will  be done at screening (blood volume  is included in  the 
sample collected  for chemistry  profile)  and urine  pregnancy tests  will be  done at Visits 2, 5 and  early 
termination.
9.2.4 Urinalysis
Urine will  be obtained at  all study  visits and sent to the clinical laboratory  at University Hospitals  
Cleveland Medical Center for determination  of color,  specific gravity, pH,  protein, glucose, ketones,  and blood.
9.3 Research Assessments
9.3.1 Serum Measurements of  Inflammatory  Mediators
40-mL of whole  blood will  be collected and  placed  in serum  separator tubes at Visits 2 (Day 1), 3 (Day  
7), and  5 (Day 28).  Samples will be centrifuged.  The serum  will be  removed, aliquoted, and frozen  at -80oC.  
Specimens will  be batched and  analyzed  for calprotectin, MPO,  GM-CSF,  IL-1β,  IL-6,  IL8, IL-17, and  TNF- 
in the Bioanalyte  Core of the CF  Research Center at Case  Western Reserve University.
9.3.2 Sputum Cell  Count and Differential
Sputum (approximately 0.065 gm) will be collected at Visits 2 (Day 1), 3 (Day 7),  and 5 (Day 28) for  
determination of white  cell counts (by hand  counting) and  differential cell counts performed by the CF- 
Therapeutics Development Network (TDN)  Center  for Interpretive  Cytology at Case Western Reserve 
University according  to the current CF-TDN SOP.   
9.3.3 Sputum Cytokine Measurements
Sputum (approximately 0.75 gm) for  determination of IL-1β, IL-6, IL-8, IL-10,  IL-17, GM-CSF, MIP-
3, TNF-, neutrophil  elastase,  R1R-anti-trypsin,  and MMP-9 will be collected at Visits 2 (Day 1),  3 (Day 7),  
and 5 (Day  28).  Specimens will be collected  in a sterile specimen cups. Sputum  will be processed according to 
the current CF-TDN SOP.  Aliquots will be batched and  analyzed  in the Bioanalyte  Core  of the CF  Research 
Center at Case Western  Reserve University.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 42 of 739.3.4 Quantitative Bacteriology
Sputum (approximately 0.5 gm) will be collected at Visits 2 (Day 1), 3 (Day 7),  and 5 (Day 28) for  
culture.  All sputum  specimens will be collected in a sterile specimen cup, Quantitative culture for typical CF 
pathogens will be  performed in the clinical microbiology laboratory at  University Hospitals Cleveland Medical 
Center.  
9.3.5 Respiratory and Systemic Symptoms Questionnaire (RSSQ)
Investigators or their designee will interview  each subject to  complete an RSSQ (Boehringer Ingelheim), 
which is  designed to capture signs and symptoms, at each  study  visit and for any other encounter for increased  
respiratory symptoms.  Such encounters may occur between study visits and include unscheduled visits and phone encounters. The RSSQ  must be completed prior to  any other study procedures.
9.3.6 Cystic  Fibrosis Respiratory  Symptom Diary (CFRSD)
Study participants will complete the CFRSD (University of Washington) five times,  at Visits 2-5 and 
once at home between  Visits 4 and 5. The  CFRSD  will also  be completed  if the subject has an acute illness  visit 
between Visit  2 and  Visit  5. The  CFRSD  is designed t o capture a change in  symptoms  and to quantify  their  
severity and magnitude for  the previous 24 hours during periods of stability,  medically treated pulmonary 
exacerbations, and  recovery  from pulmonary exacerbations. The CFRSD will be reviewed at Visits 2-5, during 
Phone Call  #2, and  at any applicable Acute  Illness Visit/Early Termination  Visit.   The CFRSD may be reviewed 
after the RSSQ is  performed but must be reviewed  prior to  any other study procedures.
9.4 Screening Assessments for  Bone Marrow Collection
9.4.1 Donor History  Questionnaire  (DHQ) for  Healthy Volunteers Participating in the Bone Marrow 
Collection
The DHQ and  its related materials (e.g., Medication Deferral List, Donor Educational Materials) will be 
used as a tool to screen donors for communicable disease  risk factors. The DHQ and  related documents 
will be obtained  from the American  Association of Blood Banks (AABB) website.
9.4.2 Measurements of Infectious  Disease  Markers for Healthy Volunteers Participating in the Bone  
Marrow Collection
Blood (28ml) will be  obtained and sent to the Indiana Blood Center for determination of the following 
infectious disease markers:  hepatitis B surface  antigen (HBsAg), hepatitis C virus (HCV), human 
immunodeficiency virus (HIV1,2), hepatitis B core antibody (HBcore), human T-cell lymphotropic virus types  I 
and II  (HTLVI/II), blood group and Rh antigen  (ABORh),  antibody screen (AbScr),  Treponema  pallidum; 
cytomegalovirus (CMV),  HIV nucleic acid test (HIVNAT), hepatitis C nucleic  acid test (HCVNAT), West  Nile  
Virus nucleic  acid test (WNVNAT),  and Chagas.  Any  positive  result will be reported to the subject (verbally  
and in writing) and  to any local  medical agencies  as required  by law, and the subject will be  instructed to  
follow-up with  a primary care  physician  or will be provided a referral to  an appropriate physician. Bone  marrow 
collection will  occur  within  7 days of  communicable disease testing, per  FDA  guidelines stipulated in  
21CFR.1271.80(b).  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 43 of 739.4.3 Cystic  Fibrosis Genetic Screening for Healthy Volunteers Participating in the Bone Marrow 
Collection
Blood (2-4ml) will be  obtained and sent to the  Center for Human Genetics Laboratory  of University 
Hospitals Cleveland Medical Center  to determine the carrier  status  of an individual  for the most  common 41 
mutations in the  CFTR gene  associated with cystic fibrosis.  Any positive  results will be  reported  to the subject  
and genetic counseling  will be provided.  
9.4.4 Measurements of Infectious  Disease  Markers for CF Subjects Participating in the Optional Bone 
Marrow Collection
Blood (10 ml) will be  obtained and sent to the University Hospitals Cleveland Medical Center 
Laboratory for  determination of the following infectious disease markers: hepatitis B and  C, syphilis  and HIV.  
Any positive result  will be  reported to the subject (verbally  and in writing) and  to any local medical agencies as  
required by law, and  the subject will be  instructed to follow-up with a  primary care physician or will be 
provided a referral to an  appropriate physician.  
9.4.5 Pregnancy Test
A serum pregnancy  test will be performed on female  subjects who  are of childbearing potential during 
the screening visit  (Visit 1)  for both healthy  volunteer donors  and CF subject donors.  For healthy volunteer  
donors, up to 2ml of blood will be obtained  for this test. For  CF subject  donors, the serum pregnancy test is  
included as  part of the  screening visit  procedures  for the  main  study described earlier.  A urine pregnancy  test 
will be performed  on female subjects of childbearing  potential at Visit  2 for heathy  volunteer  donors  and at 
Visit 1A  for CF subject donors.
10EVALUATIONS  BY VISIT
In general, the order of the  items listed below will be the chronological order in which they will be performed  at 
each study visit.  However, this  order  may change  once the logistics  are finalized for each visit prior  to the start 
of the clinical trial.
For CF Subjects:
10.1 Visit 1 (Screening Visit: Day -42 to -10)
1. Review the  study with  the subject and obtain  written  informed consent and HIPAA authorization
2. Review the “Consent for Speci men Banking” and the “Consent for Collection and Use  of your CFF  
Registry ID Number” and ensure  that the subject has checked one of the two options (Subjects who elect 
not to provide speci mens for the bio-repository or to provide  their CFF Registry ID num ber are still 
eligible for this study)
3. Assign the subject  a unique screening number
4. Perform and  record RSSQ prior  to any other study procedures
5. Record demographics  and other baseline data
6. Record medical and  surgical history, including a  history of CF, genotype, diagnosis date, and CF signs 
and symptoms
7. Record concomitant medications
8. Review inclusion/exclusion criteria
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 44 of 739. Measure  and record height and  weight without  shoes
10. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
11. Perform and  record oximetry
12. Perform a  complete physical  examination
13. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
14. Collect  urine  for clinical laboratory  test (urinalysis)
15. Collect  blood for  serum pregnancy test
16. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum at  any visit
17. Perform and  record spirometry
18. Schedule subject for Visit 2
19. Screening  procedures for optional  diagnostic bone marrow  aspiration,  if applicable:  
a.Ensure that the subject has checked  one of the two options  regarding this optional procedure on the 
consent form. (Subjects  who elect  not to complete this procedure  are still eligible for this study.)
b.Review eligibility for bone marrow aspiration
c.Collect 10  ml blood  for laboratory  tests (infectious disease  markers)
20. Record any AEs that may have  occurred  during the study visit from the time of consent
10.2 Visit 1A (if  applicable, Optional Bone Marrow  Aspiration) (Day  -35 to -14)
1. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes 
2. Review and  record interval  history
3. Review and  record any changes to concomitant medications
4. Perform urine pregnancy test if applicable
5. Perform an  abbreviated physical  exam
6. Review inclusion/exclusion criteria
7. Perform bone  marrow aspiration  
8. Subject to rest  for 30 minutes post-procedure
9. Record any AEs that may have  occurred  during the study visit
10.3 Follow-up Phone Call (if applicable, 24 (± 12)  hours after Optional Bone Marrow Aspiration)
1. Review and  record interval  history
2. Review and  record any changes to concomitant medications
3. Record any AEs that may have  occurred  since bone  marrow aspiration
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 45 of 7310.4 Visit 2 (Baseline  Visit:  Day 1)
1. Perform and  record RSSQ prior  to any other study procedures
2. Administer and  review CFRSD prior to any other study procedures and record  any AEs that occurred 
since Visit  1
3. Review and  record interval  history
4. Review and  record any changes to concomitant medications
5. Review inclusion/exclusion criteria
6. Measure  and record weight without shoes
7. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
8. Perform and  record oximetry
9. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)  and vitamin  D
10. Collect  blood for  inflammatory mediators  (calprotectin, MPO,  GM-CSF,  IL-1β,  IL-6,  IL-8, IL-17, and 
TNF-)
11. Collect  urine  for clinical laboratory  test (urinalysis)
12. Collect  urine  for pregnancy test prior  to infusion
13. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
14. Perform and  record spirometry approximately 2 hours before hMSC infusion
15. Obtain sputum for clinical laboratory tests (quantitative culture and microbiology) and  for research  tests 
(cell count with differential, IL-1β, IL-6, IL-8, IL-10, IL-17,  GM-CSF, MIP-3, TNF- , neutrophil 
elastase,  R1R-anti-trypsin, and  MMP-9).  Subjects will  be asked to provide sputum  via spontaneous 
expectoration.  If a subject  is unable  to provide sputum  spontaneously, then the subject may undergo 
sputum induction according to the  current TDN SOP.  Any  AEs related to  the sputum procedure will be 
recorded.
16. Temperature, blood pressure, heart rate, respiratory rate and  oxygen-saturation  are measured prior to the 
infusion.  Subjects should be seated for 5 minutes prior  to obtaining vital signs.
17. Perform a  complete physical  examination  
18. Infusion of  hMSCs
19. Temperature, blood pressure, heart rate, respiratory rate and  oxygen-saturation  are measured prior to 
infusion and at  10 (±  5), 20  (± 5), 30 (± 5), 60 (±  15), and 90 (± 15) minutes and 2 hours (± 15 minutes) 
and 4 hours (±  15 minutes) post-infusion completion and  then every 4 (±  15 minutes)  hours for the remainder 
of the  24-hour observation period.  Subjects should be seated or lying down for 5 minutes prior to  
obtaining vital  signs.
20. Administer 3 puffs  of albuterol 15 minutes (± 15 minutes)  after the completion  of the hMSC infusion if 
subject is likely  to require  induction  to obtain sputum  during  the visit
21. Perform and  record spirometry 30 minutes and 4 hours (± 15 minutes) after the completion of  the hMSC 
infusion
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 46 of 7322. Monitor study participant for 24 hours (± 30 minutes) after completion of the infusion
23. Record any AEs that may have  occurred  during the study visit
10.5 Visit 2 (Baseline  Visit:  Day 2)
1. Perform and  record RSSQ prior  to any other study procedures
2. Review and  record interval  history
3. Review and  record any changes to concomitant medications
4. Measure  and record weight without shoes
5. Perform and  record vital signs, including a blood  pressure after the subject has been seated or lying 
down for  5 minutes
6. Perform and  record oximetry
7. Perform a  complete physical  examination
8. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
9. Collect  urine  for clinical laboratory  test (urinalysis)
10. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
11. Perform and  record spirometry 24 hours (± 1 hour) after the  completion of the hMSC infusion
12. Schedule subject for Telephone  Call  Visit 1 and for Visit 3.
13. Record any AEs that may have  occurred  during the study visit
10.6 Telephone Call 1 (Day 4 or 5)
1. Review and  record interval  history since Visit 2
2. Perform and  record RSSQ 
10.7 Visit 3 (Day  7 ± 2)
1. Review and  record RSSQ prior  to any other study  procedures
2. Administer and  review CFRSD prior to any other study procedures and record  any AEs that occurred 
since Visit  2
3. Review and  record interval  history
4. Review and  record any changes to concomitant medications
5. Measure  and record weight without shoes
6. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
7. Perform and  record oximetry
8. Perform abbreviated physical examination
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 47 of 739. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
10. Collect  blood for  inflammatory mediators  (calprotectin, MPO,  GM-CSF,  IL-1β,  IL-6,  IL-8, IL-17, and 
TNF-)
11. Collect  urine  for clinical laboratory  test (urinalysis)
12. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
13. Perform and  record spirometry
14. Obtain sputum for clinical laboratory tests (quantitative culture and microbiology) and  for research  tests 
(cell count with differential, IL-1β, IL-6, IL-8, IL-10, IL-17,  GM-CSF, MIP-3, TNF- , neutrophil 
elastase,  R1R-anti-trypsin, and  MMP-9).  Subjects will  be asked to provide sputum  via spontaneous 
expectoration.  If a subject  is unable  to provide sputum  spontaneously, then the subject may undergo 
sputum induction according to the  current TDN SOP. Any  AEs related to  the sputum procedure will be 
recorded
15. Schedule subject for Visit 4
16. Record any AEs that may have  occurred  during the study visit 
10.8 Visit 4 (Day  14 ± 2)
1. Perform and  record RSSQ prior  to any other study procedures
2. Administer and  review CFRSD prior to any other study procedures and record  any AEs that occurred 
since Visit  3
3. Distribute CFRSD that the subject  must complete between Visit 4 and Visit 5
4. Review and  record interval  history
5. Review and  record any changes to concomitant medications
6. Measure  and record weight without shoes
7. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 
minutes.
8. Perform and  record oximetry
9. Perform abbreviated physical examination
10. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
11. Collect  urine  for clinical laboratory  test (urinalysis)
12. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
13. Perform and  record spirometry
14. Schedule Subject  for Telephone Call 2 and for Visit 5
15. Record any AEs that may have  occurred  during the study visit 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 48 of 7310.9 Telephone Call 2 (Day 21 ± 2)
1. Review and  record interval  history since Visit 4
2. Perform and  record RSSQ 
3. Review CFRSD and record  any AEs that occurred since  Visit 4
10.10 Visit 5 (Day  28 ± 2)
1. Review and  record RSSQ prior  to any other study  procedures
2. Administer and  review CFRSD prior to any other study procedures and record  any AEs that occurred 
since Telephone  call 2
3. Review and  record interval  history
4. Review and  record any changes to concomitant medications
5. Measure  and record weight without shoes
6. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
7. Perform and  record oximetry
8. Perform complete physical examination
9. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
10. Collect  blood for  inflammatory mediators  (calprotectin, MPO,  GM-CSF,  IL-1β,  IL-6,  IL-8, IL-17, and 
TNF-)
11. Collect  urine  for clinical laboratory  test (urinalysis)
12. Collect  urine  for pregnancy test
13. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
14. Perform and  record spirometry
15. Obtain sputum for clinical laboratory tests (quantitative culture and microbiology) and  for research  tests 
(cell count with differential, IL-1β, IL-6, IL-8, IL-10, IL-17,  GM-CSF, MIP-3, TNF- , neutrophil 
elastase,  R1R-anti-trypsin, and  MMP-9).  Subjects will  be asked to provide sputum  via spontaneous 
expectoration.  If a subject  is unable  to provide sputum  spontaneously, then the subject may undergo 
sputum induction according to the  current TDN SOP.  Any  AEs related to  the sputum procedure will be 
recorded
16. Schedule subject for Telephone  Call  3 and  for Visit 6
17. Record any AEs that may have  occurred  during the study visit 
10.11 Telephone Call 3 (Day 56 ± 2)
1. Review and  record interval  history since Visit 5
2. Perform and  record RSSQ 
3. Record any AEs that occurred  since Visit 5
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 49 of 7310.12 Visit 6 (Month 3 ± 14 days)
1. Perform and  record RSSQ prior  to any other study procedures
2. Review and  record interval  history
3. Review and  record any changes to concomitant medications
4. Record any AEs that occurred  since Telephone call 3
5. Measure  and record weight without shoes
6. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
7. Perform and  record oximetry
8. Perform abbreviated physical examination
9. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
10. Collect  urine  for clinical laboratory  test (urinalysis)
11. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
12. Perform and  record spirometry
13. Schedule Subject  for Visit 7
14. Record any AEs that may have  occurred  during the study visit
10.13 Visit 7 (Month 6 ± 14 days)
1. Perform and  record RSSQ prior  to any other study procedures
2. Review and  record interval  history
3. Review and  record any changes to concomitant medications
4. Record any AEs that occurred  since Visit 6
5. Measure  and record weight without shoes
6. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
7. Perform and  record oximetry
8. Perform abbreviated physical examination
9. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
10. Collect  urine  for clinical laboratory  test (urinalysis)
11. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject is likely to  require induction to  
obtain sputum during the  visit
12. Perform and  record spirometry
13. Schedule Subject  for Telephone Call 4
14. Record any AEs that may have  occurred  during the study visit
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 50 of 7310.14 Telephone Call 4 (Month 12 ± 1)
1. Review and  record interval  history since Visit 7
2. Record any AEs that occurred  since Visit 7
10.15 Acute  Illness/Early  Termination Visit
1. Review and  record RSSQ prior  to any other study  procedures
2. If Acute Illness or Early Termination  Visit occurs before  Visit  5, administer and  review  CFRSD  prior  to 
any other  study  procedures and record any  AEs that occurred since last Visit or Telephone  call
3. Review and  record interval  history
4. Review and  record any changes to concomitant medications
5. Measure  and record weight without shoes
6. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
7. Perform and  record oximetry
8. Perform a  complete physical  examination
9. Collect  blood for  clinical laboratory tests (comprehensive chemistry  panel,  ESR, hs-CRP, complete 
blood count with differential,  direct  bilirubin and  LDH)
10. Collect  urine  for clinical laboratory  test (urinalysis)  
11. Collect  urine  for pregnancy test
12. Administer 3 puffs  of albuterol 15 minutes prior to  spirometry  if subject performed a  sputum  induction 
during the study
13. Perform and  record spirometry
14. Record any AEs that may have  occurred  during the study visit 
For Healthy Volunteer Subjects:
10.16 Visit 1 (Screening Visit: Day -30 to -7)
1. Review the  study with  the subject and obtain  written  informed consent and HIPAA authorization
2. Assign the subject  a unique screening number
3. Record demographics  and other baseline data
4. Record medical and  surgical history
5. Record concomitant medications
6. Review inclusion/exclusion criteria
7. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes
8. Complete  Donor History Questionnaire (DHQ)
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 51 of 739. Collect  32 ml blood for  laboratory  tests (infectious disease  markers, CMV, CF mutations).  Collect 2 ml 
blood for  serum  pregnancy test if applicable.
10. Record any AEs that may have  occurred  during the study visit from the time of consent
10.17 Visit 2 (Bone Marrow Aspiration)
1. Perform and  record vital signs, including a blood  pressure after the subject has been seated for 5 minutes 
2. Review and  record interval  history
3. Review and  record any changes to concomitant medications
4. Perform urine pregnancy test if applicable
5. Perform an  abbreviated physical  exam
6. Review inclusion/exclusion criteria
7. Perform bone  marrow aspiration  
8. Subject to rest  for 30 minutes post-procedure
9. Record any AEs that may have  occurred  during the study visit
10.18  Follow-up Phone Call (24 (± 12) hours after  Bone Marrow Aspiration)
1. Review and  record interval  history
2. Review and  record any changes to concomitant medications
3. Record any AEs that may have  occurred  since bone  marrow aspiration
11ADVERSE EXPERIENCE REPORTING  AND DOCUMENTATION
11.1 Adverse  Events
An AE  is any  untoward  medical occurrence in a  clinical investigation of a patient  administered  a 
pharmaceutical product and that does not necessarily  have a  causal  relationship with the treatment that occurs  
from the time  of consent  through Telephone  Call 4 (Month  12 ±1).  An AE is therefore any  unfavorable and 
unintended sign (including an abnormal  laboratory  finding),  symptom or disease temporally associated  with the  
administration of an  investigational  product, whether  or not  related to  that investigational product.  An 
unexpected AE is one of a type not identified  in nature, severity, or frequency in  the current  Investigator’s  
Brochure or  of greater severity or frequency  than expected based  on the  information  in the Investigator’s 
Brochure.
The Investigator or Research Coordinator will probe, via discussion with  the subject,  for the occurrence 
of AEs  during  each  subject visit and record the information in the  site’s  source documents.  AEs will be 
recorded in the  subject CRF.   AEs will be described by duration (start and stop  dates  and times), severity, 
outcome, treatment  and relation  to investigational  product, or if  unrelated,  the cause.
AE Severity
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 52 of 73The NCI’s CTCAE Version 4.0, summarized  in Table  2 below,  should be used to assess and grade AE 
severity, including  laboratory abnormalities judged to  be clinically  significant.  It should be pointed  out that  the 
term “severe”  is a measure of intensity and that a severe  AE is not necessarily serious.
Table 2.  AE Severity  Grading (based on NCI’s  CTCAE  Version 4.0)
Severity (Toxicity Grade) Description
Grade 1  Mild; asymptomatic  or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental  ADL*.
Grade 3  Severe or  medically significant but not immediately life-
threatening; hospitalization or prolongation of hospitalization indicated; disabling;  limiting  self care ADL**.
Grade 4  Life-threatening consequences; urgent  intervention  indicated.
Grade 5 Death related to AE.
A Semi-colon  indicates ‘or’ within the  description of the grade.
Activities of Daily  Living  (ADL) 
*Instrumental ADL  refer  to preparing meals,  shopping for groceries  or clothes,  using the telephone, 
managing money,  etc. 
**Self care ADL refer to bathing, dressing and  undressing, feeding self,  using the toilet, taking 
medications, and not bedridden.
AE Relationship to Investigational Product
The relationship of an AE  to the  study  drug  should  be assessed using  the following the guidelines in  
Table 3.
Table 3.  AE Relationship to Investigational Product
Relationship
to DrugComment
Definitely Previously known toxicity of agent; or an event  that follows a reasonable  
temporal sequence from  administration of the drug; that follows a  known or 
expected response pattern to  the suspected  drug; that  is confirmed by stopping  
or reducing  the dosage of the drug; and that is not explained by any other 
reasonable hypothesis.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 53 of 73Relationship
to DrugComment
Probably An event that  follows a reasonable  temporal sequence from administration of 
the drug;  that follows a known or expected response pattern to  the suspected 
drug; that  is confirmed by stopping or reducing the dosage of the drug;  and 
that is unlikely to  be explained by the known  characteristics of the subject’s  
clinical state or by other interventions.
Possibly An event that  follows a reasonable  temporal sequence from administration of 
the drug;  that follows a known or expected response pattern to  that suspected  
drug; but that  could  readily have  been  produced by a number of other factors.
Unrelated An event that  can be determined with certainty to have no relationship to the 
investigational product.
11.2 Serious Adverse Events (SAE)
An SAE is  defined as any AE occurring at any  dose that results in  any of the following outcomes:
death
a life-threatening adverse experience
inpatient hospitalization or prolongation of  existing  hospitalization
a persistent or  significant disability/incapacity
a congenital anomaly/birth defect 
Other important medical  events may also be considered an SAE when,  based  on appropriate  medical 
judgment, they jeopardize the subject  or require intervention to  prevent one  of the outcomes listed. 
11.2.1 Serious Adverse Experience Reporting
All SAEs will  be documented (whether or not related to investigational product) on a SAE Report Form. 
The collection period for all SAEs will begin after informed consent is obtained and end  at Telephone Call 4 
(Month 12 ±1).
All SAEs will  be reviewed by the  site investigator and sent  to the TDNCC,  within one business  day of 
the site  learning  of the  event.  The  site will scan  and email or fax  the SAE report to:
Email address:   31Tcfsaesfacsys@seattlechildrens.org31T
Direct dial fax number:  (206) 985-3278
Study staff will notify the  TDNCC of additional  information or follow-up to an initial SAE Report  as 
soon as relevant  information is available.   Follow-up information is reported on an SAE Report Form.
In accordance with the  standard operating  procedures and policies of the local IRB, the site investigator will 
report SAEs to  the IRB.  SAEs will be reported  to the FDA in  accordance with 21 CFR  312.32.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 54 of 7311.3 Medical  Monitoring
TDNCC Medical Monitoring  Group  should  be contacted directly  at this number to  report medical 
concerns or  questions regarding safety:
Pager: (800) 341-0961 
12DISCONTINUATION AND REPLACEMENT  OF SUBJECTS
12.1 Withdrawal of Subjects and  Drop-outs 
A subject  may  be discontinued from the  study at any time if  the subject, the investigator feels that it is 
not in the subject’s  best interest to continue.  The following is a list of possible reasons for study or treatment 
discontinuation: 
Subject withdrawal of consent
Subject is not compliant with study procedures
Adverse event
Lost to follow-up
Physician request for early termination of study
If a subject  experiences  an AE, the subject  will be followed and treated by the Investigator or the  
subject’s physician  until the abnormal parameter  or symptom  has resolved or stabilized.  Subjects will be 
encouraged to  complete  an Early  Termination Visit.
All subjects are free to withdraw from participation at any time, for any reason,  specified  or unspecified, 
and without prejudice. If the subject withdraws  from the  study and  also withdraws consent for disclosure of  
future information, no further evaluations should be performed, and no additional data  should be collected. The 
Investigator may  retain and continue  to use any  data  collected before  such withdrawal of consent.  Any samples  
already being  analyzed will be completed and any  stored samples will be destroyed if  still linkable.
Reasonable attempts will be made  by the investigator to  provide a reason  for subject withdrawals.  The  
reason for  the subject’s withdrawal from the  study  will be specified  in the subject’s  source  documents.  Subjects 
who withdraw from  the study will be replaced if they withdraw  before Visit 5.  Refer  to Section 10 for early 
termination procedures.  If a subject withdraws on the day  of hMSC infusion,  then the Early Termination Visit  
will be performed  on Day 4-9.
13PROTOCOL  VIOLATIONS
A protocol  violation  occurs when the  subject or investigator, fails to adhere to  significant  protocol 
requirements affecting the inclusion, exclusion,  subject  safety  and primary endpoint criteria.   Protocol 
Violations for  this study include,  but are  not limited to, the following: 
Failure to  meet inclusion/exclusion criteria
Use of a prohibited concomitant medication
Failure of the  investigators or study staff to comply  with  Good Clinical Practice (GCP) guidelines will 
also result  in a protocol violation. The  medical  monitor will determine if  a protocol violation  will result in  
withdrawal of  a subject.  When a protocol  violation occurs, it will be discussed with the investigator and a  
Protocol Violation  Form  detailing  the violation will be  generated. This  form will be signed  by the Investigator. 
A copy of  the form  will be filed  in the site’s regulatory binder.  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 55 of 7314DATA  SAFETY MONITORING 
The Cystic  Fibrosis Foundation Data  Safety  Monitoring Board (DSMB) will establish  a Data 
Monitoring Committee (DMC) to review data relating to  safety  and efficacy,  to conduct and review interim 
analyses, and to ensure the continued  scientific validity  and merit of the study, according to  the Cystic Fibrosis 
Foundation Data Safety Monitoring Board Operations Manual and a DMC Charter  to be established for this 
protocol. There will be 3 interim review(s) conducted  by the DMC for the purpose of monitoring study conduct 
and assessing  subject  safety.  Enrollment  for subsequent cohorts will not begin until  after the DMC reviews the  
data for  the current  cohort  and approves  proceeding  to the next cohort.  Further details regarding the timing and 
content of  the interim reviews  is included in the statistical section below.
15STATISTICAL  METHODS AND CONSIDERATIONS (BASED UPON PRIMARY AND 
SECONDARY ENDPOINTS)
Prior to the analysis of the final study data,  a detailed Statistical Analysis Plan  (SAP)  will be  written 
describing all  analyses that will be  performed.  The SAP will contain  any modifications  to the analysis plan  
described below.  
15.1 Data  Sets  Analyzed
All eligible subjects  who are enrolled into the study and receive at least one  dose of  the investigational 
product (the  Safety Population) will be included in the  safety analysis. The analyses will be conducted on all  
data available.  Subjects with missing data  for a particular analysis will not  be included  as applicable.
15.2 Demographic  and Baseline Characteristics
Demographic and  baseline  clinical characteristics including age, gender, race, CFTR genotype, height, 
weight, oxygen saturation, sputum microbiology (presence  of P. aeruginosa, methicillin-sensitive S. aureus, 
methicillin-resistant S. aureus , and/other  Gram-negative  bacteria) and pulmonary function  will be reported  for 
each subject and  summarized overall  using descriptive  statistics such  as frequency, percentage, mean or 
median and range. F or all analyses, Baseline  will be defined as the measurement prior and closest to the 
administr ation of the infusion of hMSCs.
15.3 Analysis  of Primary Endpoint
The primary endpoint of this study is to determine the maximum tolerate  dose among  1 x 106 hMSCs/kg,  
3 x 106 hMSCs/kg,  and 5 x 106 hMSCs/kg. Safety data will be analyzed at both the individual level and the dose  
cohort level.   Safety  will be evaluated using reports  of adverse  events  (AE) and  measurements  of vital signs, 
oxygen saturation,  pulmonary function, laboratory parameters and adverse  events associated  with procedures 
(sputum induction  for those  subjects unable to spontaneously  expectorate sputum  and optional bone marrow 
aspiration). All measurements will be reported at  each time point, changes from Baseline and from the previous  
time point will  be summarized at each  time point. Premature  withdrawals  and reasons of withdrawals  will be 
listed. 
Clinically significant  AEs and alterations in vital signs, oxygen  saturation,  and pulmonary function at 
baseline, 30 minutes, 4 hours  and 24 hours after the  infusion  will be summarized by patient  and by dose cohort  
using frequency/percentage  and mean or median/range.  
Overall AEs and SAEs  in each dose cohort will be  coded by body system  and MedDRA classification 
term using frequency and percentage. Frequency and percentage of all grades and  grades ≥ 3 will be reported.  
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 56 of 73AEs among dose cohorts  will be compared  using Fisher’s exact test.  All clinically significant vita l sign and 
physical examination changes as well  as la boratory test abnormalities will be presented in AE listings. 
Mean or percentage of clinically significant AEs, alterations in vital signs  (including de creases in 
systolic  blood  pressure ≥ 20 mmHg  or  diastolic blood pr essure ≥ 10 mmH g), spirometry  measurements  (FEVR 1R 
%, FEVR 1R (Liters),  FEFR 25-75R), sputum quantitative microbiology (bacterial  colony forming units)  and 
hematology, comprehensive chemistry, ESR, hs-CRP and  urinalysis results measured at Baseline  and at the  
follow-up visits will be graphically presented.   
15.4 Analysis  of Secondary/Exploratory Endpoints
Although efficacy is  not the primary aim  of this dose escalation study, changes and patterns of change 
between MTD  and lower doses on inf lamma tory biom arkers in blood and sputum measured  at Baseline, day 7 
and day 28 will be  explored using a  mixed effects model,  mean  and standard deviation at each time point as  
well as  each patient’s case  profile  will be  graphically presented. 
15.5 Interim  Analysis
No interim statistical  analysis is planned.
15.6 Sample Size
This is  a single center Phase I study.  Enrollment of 15 subjects will be feasible and allow us to ascertain 
if there are  any clinically  meaningful infusion-related adverse effects. 
16DATA  COLLECTION, RETENTION  AND MONITORING
16.1 Data  Collection Instruments
Study personnel will enter  data  from  source documents corresponding to a  subject’s visit into the 
protocol-specific CRF when the  information  corresponding to  that visit is available.  Subjects will not be  
identified by name in the  study  database  but will  be identified by subject  number  and initials. 
All clinical information requested in this protocol  will be  entered into the CRFs.  The study data will be  
entered into  case report forms  using Medidata  Rave  eCRFs which will be  supported by the TDN Clinical Data 
Management and Programming  Core at Seattle Children’s Hospital.  Medidata Rave  is certified 21 CFR Part 11 
compliant.  Corrections to CRFs  will have  an audit trail.
The Investigator is responsible  for all information collected on subjects enrolled  in this study.  All data 
collected during the  course  of this study must be reviewed and verified for  completeness  and accuracy  by the 
Investigator.  All study records will remain at the Investigator’s site at the completion of  the study.
16.2 Data  Management Procedures
All procedures for  the handling and analysis  of data  will be conducted  using good clinical  practice 
(GCP) meeting FDA  guidelines for  the handling and analysis of data for clinical trials.   All data extracted  from 
Medidata Rave will be downloaded  to a 21 CFR  Part 11 compliant cloud-based  space where any  manipulation 
of the data  would occur.  
16.3 Data  Quality Control and Reporting
After data have been entered  into the  study database,  a system  of computerized data validation checks 
will be implemented and applied  to the database on a regular basis.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 57 of 7316.4 Archival of Data
Appropriate archiving of the database  will be completed according to Medidata  Rave procedures.    
16.5 Availability and Retention of Investigational Records
The Investigator must make  study data  accessible  to authorized personnel,  IRB,  and Regulatory Agency 
(e.g., FDA) inspectors  upon  request.   A file  for each subject  must be maintained that  includes the signed 
Informed Consent,  HIPAA  Authorization  and copies  of all  source documentation related to  that subject.  The 
Investigator must ensure the reliability and availability  of source documents from which  the information on the  
CRF was  derived.
All study  documents (subject files, signed informed  consent  forms,  CRFs,  Study File Notebook, etc.)  
must be  kept secured  for a period  of 2 years  following  marketing  of the investigational product or for 2 years 
after centers have been notified that the IND  has been discontinued.  
16.6 Monitoring
This is  a single site  investigator initiated  study.  This study will be monitored by representatives from  
the office of  the University Hospitals Cleveland Medical Center for Clinical Research and Technology per the  
monitoring plan  as described in DMC  charter.   By signing this protocol, the Investigator grants permission to 
the office of  the University Hospitals Cleveland Medical Center for Clinical Research and Technology (or 
designee), and appropriate regulatory authorities to conduct on-site monitoring  and/or auditing of all  appropriate 
study documentation. 
16.7 Subject Confidentiality
In order  to maintain subject confidentiality,  only a subject number and subject initials will identify all 
study subjects  on CRFs.  Laboratory reports, spirometry  reports,  CRU  flow sheets, and  CRU  physician  order 
sheets will contain  the subject’s  name and medical registration number. 
17ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS
The study will be  conducted according to the Declaration of Helsinki, Protection  of Human  Volunteers 
(21 CFR  50), Institutional Review  Boards (21  CFR 56), and  Obligations of Clinical Investigators (21 CFR  312).
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and  other  records  will be 
identified by a  coded number and initials only.  All non-electronic study records will be  kept in a  locked file 
cabinet/file room and code  sheets  linking a subject’s  name to a subject  identification number  will be stored 
separately in another  locked  file cabinet.  Clinical information will not  be released without written  permission  
of the subject,  except  as necessary for monitoring by the FDA.   The Investigator must  also comply with  all 
applicable privacy  regulations  (e.g., Health  Insurance Portability and Accountability  Act of 1996, EU Data  
Protection Directive 95/46/EC).
17.1 Protocol Amendments
Any amendment  to the protocol will be  the responsibility of the Principal Investigator.
A protocol  amendment intended to eliminate  an apparent immediate hazard to  subjects may be 
implemented immediately, provided  the IRB is notified  per IRB policy.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 58 of 7317.2 Institutional Review Board
The protocol  and consent form will be reviewed and  approved by the IRB at University Hospitals  
Cleveland Medical Center prior to study initiation.  Serious  adverse experiences  regardless  of causality will  be 
reported to the IRB in accordance  with the  standard operating procedures and policies of the IRB, and the 
Investigator will keep the  IRB  informed  as to the progress  of the study.  The Investigator will obtain a list  of 
IRB members  or other assurance  of compliance with regulations.
Any documents  that the IRB may need to fulfill  its responsibilities  (such as protocol, protocol  
amendments, Investigator’s Brochure, consent forms, information concerning subject  recruitment,  payment  or 
compensation procedures, or other  pertinent  information) will be submitted to the  IRB.  The IRB written  
unconditional approval of the study protocol  and the informed consent  form  will be in  the possession of the  
Investigator before  the study is initiated.   This approval must refer to  the study by exact protocol title  and 
number and should identify the documents reviewed and  the date  of review.
Protocol and/or informed consent modifications  or changes may not be initiated without prior  written 
IRB approval  except  when necessary to eliminate immediate  hazards to  the subjects  or when the change(s) 
involves only logistical  or administrative aspects  of the  study.   Such modifications  will be  submitted to the  IRB  
and written verification that the  modification was submitted  and subsequently approved  should be  obtained.   
The IRB will be  informed of revisions to other  documents  originally submitted for review; serious 
and/or unexpected adverse experiences occurring during the study in accordance with  the standard  operating  
procedures and  policies of the IRB; new  information that  may affect  adversely  the safety of the subjects of the 
conduct of  the study;  an annual  update  and/or request for re-approval; and when the study has been  completed.
17.3 Informed Consent Form 
Informed consent will be  obtained in accordance with the  Declaration  of Helsinki, ICH  GCP, US Code  
of Federal  Regulations for Protection  of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 56,  
Subpart A), the Health Insurance  Portability and  Accountability Act  (HIPAA, if applicable), and local 
regulations.
The Investigator will prepare the informed  consent form  and HIPAA authorization for submission to  the 
IRB.  The consent  form generated by the Investigator must  be approved by the IRB.  The written consent 
document will embody  the elements  of informed consent as described in  the International Conference on 
Harmonisation and  will also  comply with local  regulations. The Investigator will retain  an IRB-approved  copy 
of the Informed Consent Form for  the study file.
A properly executed, written, informed  consent  will be obtained from each subject prior to  entering the 
subject into the trial.  Information  should  be given in both oral and written  form and subjects must be given 
ample opportunity to inquire about details of  the study.   If a subject is unable  to sign the informed consent form 
(ICF) and the HIPAA authorization, a legal  representative may sign for the subject.   A copy of the signed 
consent form will be  given to the subject  or legal representative  of the subject  and the original will be 
maintained with  the subject’s  records.
17.3.1 Consent for  Collection  and Use of CFF Registry ID Number and Sample Banking
Any remaining research  samples will be stored for future studies  in secured -80oC freezers in  the 
laboratories of the  Cystic Fibrosis Research Center  at Case  Western Reserve  University/University Hospitals 
Cleveland Medical Center.    Samples will be labeled with the date, the subject’s unique identifying number, and 
visit number. 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 59 of 73To facilitate possible future evaluation of long-term outcomes infor mation  from  all patients who screen  
for this  study, consent will also be sought to collect the subject’s  CFF Registry ID num ber at the screening visit.  
The CFF reg istry collec ts data on all CF patie nts followed at CFF-accredited care centers at each clinical 
encoun ter, at each hospitalization  or course  of ho me IV antibiotics, and via a year-end survey. If  specif ic 
consent  is given to collec t this number, the patient’ s CF registr y number will be recor ded in the CRF.
17.4 Publications  
The preparation and submittal for publication of manuscripts containing  the study  results shall be in  
accordance with  a process determined by mutual written  agreement among the study funding  agency  (Cystic 
Fibrosis Foundation Therapeutics) and  participating institutions.  The publication  or presentation of any  study  
results shall  comply with all  applicable  privacy laws, including,  but not limited to, the Health Insurance 
Portability and  Accountability Act of 1996. 
17.5 Investigator Responsibilities
1.Conduct the  study in accordance with the protocol and only make changes after  obtaining appropriate 
approval, except when to protect the  safety,  rights or welfare of subjects.
2.Personally conduct or  supervise the study (or investigation).
3.Ensure  that the  requirements relating  to obtaining informed consent and IRB review and approval  meet 
federal guidelines,  as stated  in § 21 CFR,  parts 50 and 56.
4.Report  to the medical  monitor any AEs that occur in the  course  of the study, in accordance with  §21 CFR 
312.64.
5.Ensure  that all associates, colleagues and  employees assisting in the conduct of the study are informed 
about their obligations in meeting the above  commitments.
6.Maintain adequate and accurate records in accordance with  §21 CFR 312.62 and to make those records 
available for  inspection.
7.Ensure  that an  IRB  that complies  with the requirements of §21 CFR part 56 will be responsible for initial 
and continuing review  and approval of the clinical  study.
8.Promptly report to the IRB all changes in the research activity and all  unanticipated problems involving 
risks to  subjects  or others (to include  amendments  and IND safety reports).
9.Seek  IRB approval before any  changes  are made  in the research study, except  when necessary  to eliminate 
hazards to the patients/subjects.
10.Comply  with all  other requirements regarding the obligations of clinical investigators and all  other 
pertinent requirements listed in § 21 CFR part  312.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 60 of 7318APPENDIX I: DEFINITION OF A PULMONARY EXACERBATION  (MODIFIED FUCHS  
CRITERIA)95
An exacerbation of respiratory symptoms is defined  as a subject undergoing a  change  in antibiotic 
therapy for any  4 of the following  12 signs  or symptoms:  
1.Change in sputum
2.New or increased hemoptysis
3.Increased cough
4.Increased dyspnea
5.Malaise, fatigue, or  lethargy
6.Temperature above 38 °C
7.Anorexia or weight loss
8.Sinus pain or tenderness 
9.Change in sinus discharge
10.Change in physical  examination of  the chest
11.Decrease in pulmonary function  by 10 percent or more from a  previously  recorded value
12.Radiographic changes  indicative of pulmonary  infection
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 61 of 7319APPENDIX II.  SCHEDULE OF STUDY  VISITS
Visit 1
Screen
ingVisit 2
BaselinePhone 
Call 1Visit 3 Visit 4 Phone 
Call 2Visit 5 Phone
Call 3Visit 6
and 
Visit 7Acute 
Illnessp/ 
Early 
Term. 
VisitqPhone
Call 4
Day
-42 to -
10Day
1Day
2Day
4 or 5Day
7 ± 2Day
14 ± 2Day
21 ± 2Day
28 ± 2Day
56 ± 2Month 3 
± 14 days 
and 
Month 6 
± 14 daysMonth 
12 ± 1
Informed consent X
Medical & surgical history X
Demographics and  baseline 
characteristicsX
Interval history XcX X X X X X X X X X
Review previous and concomitant therapy
X XcX X X X X X
Review inclusion/exclusion criteria
X Xc
Heighta, weight, vital  signs,  
oximetryX XcX X X X X X
Complete physical exam X XcX X X
Abbreviated physical exam X X X
Blood draw-safety labsgX XcX X X X X X
Blood draw-vitamin D Xc
Blood draw inflammatory mediatorsh
XcX X
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 62 of 73Visit 1
Screen
ingVisit 2
BaselinePhone  
Call 1Visit 3 Visit 4 Phone  
Call 2Visit 5 Phone
Call 3Visit 6
and 
Visit 7Acute  
Illnessp/ 
Early 
Term. 
VisitqPhone
Call 4
Day
-42 to -
10Day
1Day
2Day
4 or 5Day
7 ± 2Day
14 ± 2Day
21 ± 2Day
28 ± 2Day
56 ± 2Month  3 
± 14 days 
and 
Month  6 
± 14 daysMonth  
12 ± 1
Serum pregnancy test 
(if applicable)X
Urinalysis X XcX X X X X X
Urine pregnancy test  
(if applicable)XcX X
Spirometry X Xc, d, eXoX eX X eX X
Acquisition of  sputumfXcX X
Sputum quantitative  
bacteriologyXcX X
Sputum cell count XcX X
Sputum cytokine  
measurementsiXcX X
RSSQ X XcX XjX X XjX XjX X
CFRSD X X X X X Xk
Diagnostic bone marrow exam (optional)b
X
Investigational product (hMSC) infusion
Xl, m, n
Adverse events X X X X X X X X X X X X
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 63 of 73a Height will  only be obtained one time in the study  at the Screening Visit
b See Appendix IIa for  Schedule  of Events for Stem Cell Collection from CF  Donors
c Other procedures  and collections should  be done prior to infusion of stem cells
d On the day of hMSC infusion, spirometry should  be performed approximately 2 hours prior to infusion and  30 minutes  (± 15 minutes) and 4 hours (±15 minutes) 
after completion of infusion
e At visits  2, 4,  and 6, spirometry should be  performed  prior to the  acquisition of sputum
f Sputum can be collected  by spontaneous  expectoration.   In those subjects unable  to spontaneously expectorate, sputum may be induced by inhalation with  3% 
hypertonic saline using  the current TDN  SOP
g CBC with differential, comprehensive chemistry panel, hs-CRP,  ESR,  direct bilirubin and LDH
h Calprotectin, MPO,  GM-CSF, IL-1β, IL-6, IL8, IL-17, and  TNF-
I IL-1β, IL-6,  IL-8, IL-10, IL-17, GM-CSF, MIP-3 , TNF-, neutrophil elastase, R 1R-anti-trypsin, and  MMP-9
j RSSQ  should be  administered if any increased respiratory symptoms
k Only if Acute Illness/Early Termination Visit is prior  to Visit 5 
l MSCs  will be derived from bone marrow  samples obtained from healthy volunteers  and processed and evaluated  according to CCC  SOP  well in  advanced of 
infusion.  CF study staff will inform  CCC collaborators  when hMSCs will be  needed approximately 14 days prior to infusion.  CCC collaborators will prepare  the 
proper dose  to be  infused  based  upon the weight of the subject with CF
m Infusion  is given  by slow IV push and takes  less than 30 minutes depending upon the volume to be infused
n Subjects will be monitored in the CRU for 24 hours after the  completion  of the  infusion. Temperature,  blood pressure,  heart  rate, respiratory  rate and  oxygen-
saturation are measured  prior to infusion and at 10 (± 5), 20 (± 5), 30 (±  5), 60 (±  15), and  90 (±  15) minutes and 2 hours (±15 minutes) and 4 (± 15 minutes) hours  
post-infusion and then  every 4 (± 15 minutes) hours for the remainder of the  24-hour observation  period.    
o On Day 2, spirometry should be performed at 24 (± 1) hours after completion of infusion
p An Acute Illness Visit will be arranged for any subject who  experiences  any abrupt change in baseline clinical status,  between  Visit 2 and  Visit 5
q An Early Termination Visit will be completed for  any subject terminating study participation between Visit 2 and Visit 7.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 64 of 73APPENDIX IIa.  SCHEDULE  OF STUDY VISITS FOR OPTIONAL STEM CELL COLLECTION 
FROM CF SUBJECT DONORS
Visit 1
ScreeningVisit 1A Follow-up  Phone 
Call
Day 
-42 to -101Day
-35 to -1424 (± 12) hours 
after bone  marrow 
aspiration
Informed consent X
Interval history X X
Review previous and concomitant therapy
X X
Review inclusion/exclusion criteria
X X
Phlebotomy for infectious disease limited panel
X
Vital signs X
Urine pregnancy test  
(if applicable)X
Abbreviated physical exam X
Bone marrow  aspiration of 
the posterior iliac crestX
Adverse events X X X
1The Visit 1 Screening window in this table refers to the main  study (for  consistency  with the table in  Appendix 
II).  If a CF subject plans to participate in the optional stem cell collection procedure at Visit 1A,  then the Visit 
1 Screening must be  completed by Day  -14 or earlier in order to complete Visit 1A and  Visit  1 at the 
appropriate times.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 65 of 73APPENDIX IIb.   SCHEDULE OF STUDY VISITS FOR  STEM CELL COLLECTION FROM 
HEALTHY VOLUNTEER DONORS
Visit 1
ScreeningVisit 2 Follow-up  Phone 
Call
Day
-30 to -7Day
124 (± 12) hours 
after bone  
marrow  
aspiration
Informed consent X
Medical & surgical history X
Demographics and  baseline 
characteristicsX
Interval history X X
Review previous and concomitant therapy
X X X
Review inclusion/exclusion criteria
X X
DHQ X
Serum pregnancy test X
Phlebotomy for infectious disease panel including  CMV
X
Phlebotomy for CF  mutation 
screeningX
Vital signs X X
Urine pregnancy test  
(if applicable)X
Abbreviated physical exam X
Bone marrow  aspiration of 
the posterior iliac crestX
Adverse events X X X
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 66 of 7320REFERENCES
1. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L.  Approaches to phase 1 clinical trial 
design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering  committee. Clin Cancer Res.  Mar 15 2010;16(6):1726-1736.
2. Davis  PB, Drumm  M, Konstan MW. Cystic fibrosis.  Am J Respir.Crit Care Med. 
11/1996 1996;154(5):1229-1256.
3. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 5/30/2009 2009;373(9678):1891-1904.
4. Konstan MW,  Doring  G, Heltshe SL, et al. A randomized double blind, placebo 
controlled phase 2 trial  of BIIL 284 BS  (an LTB4 receptor  antagonist) for  the 
treatment of  lung disease in children and adults with  cystic fibrosis. J  Cyst Fibros. 
Mar 2014;13(2):148-155.
5. Mogayzel  PJ, Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary 
guidelines. Chronic medications  for maintenance of  lung  health. Am J Respir Crit 
Care Med. Apr 1 2013;187(7):680-689.
6. Inamdar  AC,  Inamdar AA. Mesenchymal stem cell therapy in  lung disorders: 
pathogenesis of lung diseases and mechanism  of action of mesenchymal  stem  cell. 
Exp Lung Res.  Oct 2013;39(8):315-327.
7. Gebler  A, Zabel  O, Seliger  B. The immunomodulatory capacity of mesenchymal 
stem cells. Trends Mol Med.  Feb 2012;18(2):128-134.
8. Glennie S, Soeiro  I, Dyson  PJ, Lam EW,  Dazzi F. Bone  marrow mesenchymal stem 
cells induce division  arrest anergy of activated T cells. Blood. Apr  1 
2005;105(7):2821-2827.
9. Guo M, Sun  Z, Sun QY,  et al. A modified haploidentical nonmyeloablative  
transplantation without T cell  depletion  for high-risk acute leukemia: successful 
engraftment and  mild  GVHD. Biology of blood and marrow transplantation  : 
journal of the American Society for Blood and Marrow Transplantation. Aug 2009;15(8):930-937.
10. Guan XJ, Song L, Han FF, et al. Mesenchymal  stem cells  protect  cigarette smoke-
damaged lung  and pulmonary function  partly via VEGF-VEGF receptors. J  Cell 
Biochem. Feb  2013;114(2):323-335.
11. Zhen G, Liu H, Gu N, Zhang H, Xu Y, Zhang Z. Mesenchymal  stem cells 
transplantation protects against  rat pulmonary emphysema. Front Biosci. 
2008;13:3415-3422.
12. Gupta  N, Su X, Popov B, Lee  JW, Serikov  V, Matthay MA. Intrapulmonary 
delivery of  bone marrow-derived mesenchymal stem cells  improves survival  and 
attenuates endotoxin-induced  acute  lung injury in mice.  J Immunol.  Aug  1 
2007;179(3):1855-1863.
13. Nemeth K, Leelahavanichkul  A, Yuen PS,  et al. Bone marrow  stromal cells 
attenuate sepsis via prostaglandin E(2)-dependent reprogramming  of host 
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 67 of 73macrophages to increase their interleukin-10 production. Nat Med. Jan 2009;15(1):42-49.
14. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived  mesenchymal  stem cells in  
repair of  the injured lung. Am J Respir  Cell Mol Biol.  Aug  2005;33(2):145-152.
15. Shigemura  N, Okumura M, Mizuno S, Imanishi Y, Nakamura  T, Sawa Y.  
Autologous transplantation of adipose tissue-derived stromal cells ameliorates 
pulmonary emphysema. Am J Transplant. Nov 2006;6(11):2592-2600.
16. Islam MN, Das  SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-
derived stromal cells to pulmonary  alveoli protects against  acute  lung  injury. Nat  
Med. May 2012;18(5):759-765.
17. Zhu YG, Feng XM, Abbott J, et al. Human  mesenchymal stem cell microvesicles 
for treatment of Escherichia coli  endotoxin-induced  acute  lung injury in mice. Stem 
Cells. Jan 2014;32(1):116-125.
18. Krasnodembskaya A, Song Y, Fang X, et al.  Antibacterial effect  of human  
mesenchymal stem cells is  mediated  in part  from secretion of the  antimicrobial 
peptide LL-37. Stem Cells. Dec 2010;28(12):2229-2238.
19. Bonfield TL,  Lennon DP, Ghosh SK,  Dimarino AM, Weinberg A, Caplan AI. 
Therapy aides in infection and inflammation  resolution in the murine  model of 
cystic fibrosis lung disease.  Stem Cell Discovery. 2013;3:138-159.
20. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of  mesenchymal  
stromal cell  therapy. Cytotherapy. Sep 2010;12(5):576-578.
21. von Bahr  L, Batsis  I, Moll G, et al.  Analysis of tissues following mesenchymal 
stromal cell  therapy in  humans indicates  limited  long-term  engraftment and  no 
ectopic tissue  formation. Stem Cells. Jul 2012;30(7):1575-1578.
22. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with  mesenchymal 
stromal cells (SafeCell): a  systematic  review and meta-analysis  of clinical trials. 
PLoS One. 2012;7(10):e47559.
23. Weiss  DJ, Casaburi R,  Flannery R, LeRoux-Williams M,  Tashkin DP. A placebo-
controlled, randomized trial of mesenchymal stem cells in COPD. Chest. Jun 2013;143(6):1590-1598.
24. Hatzistergos  KE, Blum A, Ince  T, Grichnik  JM, Hare JM. What is the oncologic 
risk of stem cell treatment for heart disease? Circ Res. May 27 2011;108(11):1300-1303.
25. Chang YS, Ahn SY, Yoo HS,  et al. Mesenchymal stem cells for bronchopulmonary  
dysplasia: phase 1 dose-escalation clinical trial. J Pediatr.  May 2014;164(5):966-
972 e966.
26. Skrahin A, Ahmed  RK, Ferrara G, et al. Autologous  mesenchymal  stromal cell 
infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis:  an open-label phase  1 safety  trial.  Lancet Respir  Med. Feb 
2014;2(2):108-122.
27. Wang D, Zhang H, Liang J, et al.  Allogeneic  mesenchymal stem cell  transplantation 
in severe and  refractory  systemic lupus  erythematosus: 4 years of experience. Cell  
Transplant. 2013;22(12):2267-2277.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 68 of 7328. Forbes GM, Sturm MJ, Leong RW, et al.  A phase 2 study of allogeneic 
mesenchymal stromal  cells  for luminal Crohn's disease  refractory to  biologic 
therapy. Clin  Gastroenterol  Hepatol. Jan 2014;12(1):64-71.
29. Zheng GP, Ge MH, Shu Q, Rojas M, Xu J. Mesenchymal  stem cells in  the 
treatment of  pediatric diseases.  World journal of pediatrics : WJP. Aug 
2013;9(3):197-211.
30. Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with  
mesenchymal stromal  cells:  a phase  I study on 40 adult  and pediatric patients. 
Biology of blood  and marrow transplantation : journal of the American Society for 
Blood and Marrow Transplantation. Mar  2014;20(3):375-381.
31. Kurtzberg  J, Prockop S, Teira P, et al. Allogeneic human  mesenchymal  stem cell 
therapy (remestemcel-L, Prochymal) as a  rescue  agent for severe refractory acute 
graft-versus-host disease in pediatric patients. Biology  of blood  and marrow 
transplantation :  journal of the American  Society  for Blood  and Marrow  
Transplantation. Feb 2014;20(2):229-235.
32. Bonfield TL,  Panuska JR,  Konstan MW,  et al. Inflammatory  cytokines in cystic 
fibrosis lungs. Am J  Respir  Crit Care Med. Dec 1995;152(6  Pt 1):2111-2118.
33. Heeckeren A, Walenga  R, Konstan MW,  Bonfield  T, Davis PB, Ferkol T.  
Excessive inflammatory response of cystic fibrosis mice  to bronchopulmonary  
infection with Pseudomonas  aeruginosa. J Clin Invest. Dec 1 1997;100(11):2810-
2815.
34. Soltys J, Bonfield  T, Chmiel J, Berger  M. Functional IL-10  deficiency in the lung 
of cystic fibrosis (cftr(-/-)) and  IL-10 knockout  mice  causes increased  expression 
and function of  B7 costimulatory  molecules  on alveolar macrophages.  J Immunol.  
Feb 15 2002;168(4):1903-1910.
35. Dasenbrook EC, Checkley W, Merlo  CA, Konstan MW, Lechtzin N, Boyle MP. 
Association between respiratory  tract  methicillin-resistant Staphylococcus  aureus  
and survival in cystic fibrosis. JAMA.  June  2010 2010;303(23):2386-2392.
36. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS,  Caplan AI. Ex  vivo  
expansion and  subsequent infusion of human bone marrow-derived stromal  
progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone marrow transplantation. Oct 1995;16(4):557-564.
37. Koc ON,  Day  J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic 
mesenchymal stem cell infusion for treatment of  metachromatic leukodystrophy 
(MLD) and  Hurler syndrome (MPS-IH). Bone marrow transplantation.  Aug 
2002;30(4):215-222.
38. Lazarus HM, Koc  ON,  Devine  SM, et al. Cotransplantation of HLA-identical 
sibling culture-expanded mesenchymal stem cells and  hematopoietic  stem cells  in 
hematologic malignancy  patients.  Biology of blood and marrow transplantation : 
journal of the American Society for Blood and Marrow Transplantation. May 2005;11(5):389-398.
39. Couban S, Simpson  DR, Barnett  MJ, et al. A randomized multicenter comparison of 
bone marrow and peripheral  blood in recipients of matched sibling allogeneic 
transplants for myeloid malignancies. Blood. Sep 1 2002;100(5):1525-1531.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 69 of 7340. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone  marrow as 
compared with peripheral-blood cells from  HLA-identical relatives in  patients  with 
hematologic cancers. N Engl J Med.  Jan 18 2001;344(3):175-181.
41. Krivit W,  Peters  C, Shapiro  EG. Bone marrow transplantation as effective treatment 
of central  nervous system disease in globoid cell leukodystrophy, metachromatic 
leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly  syndromes,  and Gaucher 
disease type III.  Curr Opin Neurol. Apr 1999;12(2):167-176.
42. Caplan  AI. Why are  MSCs  therapeutic? New data: new insight. J Pathol. Jan  
2009;217(2):318-324.
43. Stenderup K, Justesen J,  Clausen  C, Kassem M. Aging is associated with decreased 
maximal life span and accelerated  senescence  of bone  marrow stromal  cells. Bone. 
Dec 2003;33(6):919-926.
44. Lazzarotto-Silva C, Binato R, Rocher BD, et al. Similar proteomic profiles of human mesenchymal stromal cells from different  donors. Cytotherapy. 
2009;11(3):268-277.
45. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A,  Barry F. Reduced 
chondrogenic and  adipogenic activity  of mesenchymal stem cells from patients with 
advanced osteoarthritis. Arthritis Rheum. Mar 2002;46(3):704-713.
46. Bacigalupo A, Valle M, Podesta M, et al. T-cell  suppression mediated by 
mesenchymal stem cells is  deficient in patients  with severe aplastic anemia.  Exp 
Hematol. Jul 2005;33(7):819-827.
47. Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial progenitors are  
defective in systemic sclerosis. Arthritis Rheum. Aug 2006;54(8):2605-2615.
48. Kastrinaki MC, Sidiropoulos P, Roche S, et al. Functional, molecular  and proteomic 
characterisation of  bone  marrow mesenchymal  stem  cells  in rheumatoid arthritis. 
Ann Rheum Dis. Jun 2008;67(6):741-749.
49. Bocelli-Tyndall C,  Bracci L, Spagnoli G, et al. Bone  marrow mesenchymal stromal  
cells (BM-MSCs) from healthy  donors and auto-immune disease patients reduce the 
proliferation of  autologous- and allogeneic-stimulated lymphocytes in vitro. 
Rheumatology (Oxford). Mar 2007;46(3):403-408.
50. Larghero J, Farge  D, Braccini  A, et  al. Phenotypical and functional characteristics 
of in vitro expanded  bone  marrow mesenchymal stem cells from  patients with 
systemic sclerosis.  Ann Rheum  Dis. Apr 2008;67(4):443-449.
51. Papadaki HA, Tsagournisakis M, Mastorodemos V, et al. Normal bone marrow  
hematopoietic stem  cell reserves and  normal stromal  cell function  support the  use of 
autologous stem cell transplantation in patients with multiple  sclerosis. Bone 
marrow transplantation. Dec  2005;36(12):1053-1063.
52. Mazzanti  B, Aldinucci  A, Biagioli T, et al. Differences  in mesenchymal stem cell 
cytokine profiles between MS patients and healthy  donors:  implication  for 
assessment of  disease activity and  treatment. J Neuroimmunol. Aug 13 2008;199(1-
2):142-150.
53. Ho AD, Wagner W, Franke W. Heterogeneity  of mesenchymal  stromal cell 
preparations. Cytotherapy. 2008;10(4):320-330.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 70 of 7354. Haack-Sorensen M,  Bindslev L, Mortensen  S, Friis T,  Kastrup J.  The influence of 
freezing and storage on the characteristics and functions of human mesenchymal  
stromal cells isolated for clinical use. Cytotherapy. 2007;9(4):328-337.
55. Koc ON,  Gerson  SL, Cooper BW, et al. Rapid hematopoietic recovery  after 
coinfusion of  autologous-blood stem cells and culture-expanded  marrow  
mesenchymal stem cells in advanced  breast cancer  patients  receiving high-dose 
chemotherapy. J Clin  Oncol.  Jan 2000;18(2):307-316.
56. Samuelsson H, Ringden O, Lonnies H, Le  Blanc K.  Optimizing  in vitro conditions  
for immunomodulation and  expansion of mesenchymal stromal  cells. Cytotherapy. 
2009;11(2):129-136.
57. Agashi K, Chau  DY, Shakesheff KM. The effect of delivery via narrow-bore  
needles on mesenchymal  cells. Regen Med. Jan 2009;4(1):49-64.
58. Horwitz EM, Gordon PL,  Koo WK,  et al. Isolated allogeneic bone marrow-derived 
mesenchymal cells  engraft  and stimulate growth in children with  osteogenesis 
imperfecta: Implications for cell  therapy of bone. Proc Natl Acad Sci U  S A. Jun 25 
2002;99(13):8932-8937.
59. Chen-Plotkin AS,  Vossel KA, Samuels MA, Chen  MH. Encephalopathy,  stroke,  
and myocardial infarction with DMSO use in stem cell transplantation. Neurology. Mar 13 2007;68(11):859-861.
60. Sundin  M, Ringden  O, Sundberg B, Nava  S, Gotherstrom C, Le Blanc K. No 
alloantibodies against mesenchymal stromal cells,  but presence of anti-fetal calf 
serum antibodies,  after transplantation in allogeneic hematopoietic stem cell 
recipients. Haematologica.  Sep 2007;92(9):1208-1215.
61. Brooke  G, Cook  M, Blair C, et al.  Therapeutic applications of mesenchymal 
stromal cells. Semin Cell Dev Biol.  Dec 2007;18(6):846-858.
62. Le Blanc  K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal  
stem cells to enhance engraftment  of hematopoietic stem cells. Leukemia. Aug  
2007;21(8):1733-1738.
63. Sundin  M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le  Blanc  K. 
Mesenchymal stem cells are susceptible  to human  herpesviruses,  but viral  DNA 
cannot be detected  in the  healthy seropositive individual.  Bone marrow  
transplantation. Jun  2006;37(11):1051-1059.
64. Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses.  Blood. Aug  1 
2008;112(3):532-541.
65. Le Blanc  K, Frassoni F,  Ball L,  et al. Mesenchymal stem cells for treatment of 
steroid-resistant, severe, acute graft-versus-host disease: a  phase II study. Lancet. 
May 10 2008;371(9624):1579-1586.
66. Ning H, Yang  F, Jiang M, et al.  The correlation between cotransplantation of 
mesenchymal stem cells and higher recurrence rate in  hematologic malignancy 
patients: outcome  of a pilot clinical study. Leukemia. Mar 2008;22(3):593-599.
67. Ringden O, Uzunel M, Rasmusson  I, et al. Mesenchymal  stem cells for treatment of 
therapy-resistant graft-versus-host disease. Transplantation. May 27 2006;81(10):1390-1397.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 71 of 7368. Prindull G, Zipori D. Environmental  guidance of normal and  tumor cell plasticity: 
epithelial mesenchymal transitions as a paradigm.  Blood. Apr  15 2004;103(8):2892-
2899.
69. Serakinci N, Guldberg P, Burns JS,  et al. Adult human mesenchymal stem cell as a 
target for neoplastic transformation. Oncogene. Jun 24 2004;23(29):5095-5098.
70. Greaves  M. Molecular genetics,  natural  history and the demise of childhood  
leukaemia. Eur J  Cancer. Dec  1999;35(14):1941-1953.
71. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating  from bone 
marrow-derived cells. Science. Nov 26 2004;306(5701):1568-1571.
72. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal 
stem cells. Stem  Cells. Feb  2007;25(2):371-379.
73. Bernardo  ME, Zaffaroni N, Novara F, et al. Human bone  marrow derived 
mesenchymal stem cells do not undergo  transformation after  long-term in  vitro 
culture and do not exhibit telomere maintenance mechanisms. Cancer Res. Oct  1 
2007;67(19):9142-9149.
74. Breitbach  M, Bostani  T, Roell W, et al.  Potential risks of bone marrow cell 
transplantation into infarcted hearts.  Blood. Aug 15 2007;110(4):1362-1369.
75. Rubio D, Garcia-Castro J,  Martin  MC,  et al. Spontaneous  human  adult  stem cell  
transformation. Cancer Res. Apr 15 2005;65(8):3035-3039.
76. Wang Y, Huso DL, Harrington J, et al. Outgrowth of a transformed cell population derived from normal human  BM mesenchymal stem cell  culture. Cytotherapy. 
2005;7(6):509-519.
77. Kim J, Kang JW,  Park  JH, et  al. Biological characterization of long-term  cultured 
human mesenchymal stem cells. Arch Pharm Res. Jan 2009;32(1):117-126.
78. Rosland GV, Svendsen A, Torsvik A, et  al. Long-term cultures  of bone  marrow-
derived human mesenchymal  stem cells  frequently  undergo spontaneous malignant 
transformation. Cancer Res. Jul 1 2009;69(13):5331-5339.
79. Kidd S,  Spaeth E, Klopp A, Andreeff M,  Hall  B, Marini FC.  The (in) auspicious 
role of mesenchymal stromal cells in cancer: be  it friend or foe. Cytotherapy. 
2008;10(7):657-667.
80. Tabe  Y, Konopleva M, Munsell MF, et al. PML-RARalpha is associated with 
leptin-receptor induction: the role  of mesenchymal  stem  cell-derived adipocytes in 
APL cell  survival.  Blood. Mar 1 2004;103(5):1815-1822.
81. Karnoub AE, Dash AB, Vo AP,  et al. Mesenchymal  stem cells within tumour 
stroma promote  breast cancer metastasis. Nature. Oct  4 2007;449(7162):557-563.
82. Djouad  F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem 
cells favors tumor growth in allogeneic  animals. Blood. Nov  15 2003;102(10):3837-
3844.
83. Barry F, Boynton R, Murphy M, Haynesworth S, Zaia J.  The SH-3 and SH-4 
antibodies recognize distinct epitopes on CD73  from human mesenchymal stem 
cells. Biochem Biophys Res  Commun.  Nov 30 2001;289(2):519-524.
84. Cystic Fibrosis Foundation, Patient Registry  2012 Annual Data Report.  Bethesda,  
MD 2012 2013.
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 72 of 7385. Dasenbrook EC. Cystic fibrosis and survival in patients with advanced  lung  disease. 
BMJ. 2011 2011;342:d726.
86. Rowe  SM,  Heltshe  SL, Gonska T, et  al. Clinical mechanism  of the  cystic  fibrosis 
transmembrane conductance regulator potentiator  ivacaftor in G551D-mediated 
cystic fibrosis. Am J Respir Crit Care Med. Jul 15 2014;190(2):175-184.
87. Chmiel JF, Berger  M, Konstan MW.  The role of inflammation in  the 
pathophysiology of CF lung disease.  Clin Rev Allergy  Immunol.  Aug  2002;23(1):5-
27.
88. Bonfield TL,  Caplan AI. Adult mesenchymal stem cells: an innovative therapeutic 
for lung diseases. Discov Med. Apr  2010;9(47):337-345.
89. Jiang Y, Jahagirdar  BN,  Reinhardt RL, et al. Pluripotency of mesenchymal stem 
cells derived from  adult marrow.  Nature. Jul 4 2002;418(6893):41-49.
90. Wang G, Bunnell BA,  Painter RG, et al. Adult stem cells  from bone marrow  stroma 
differentiate into airway  epithelial cells: potential therapy for cystic fibrosis. Proc  
Natl Acad Sci  U S A.  Jan 4 2005;102(1):186-191.
91. Antunes MA, Laffey JG, Pelosi P, Rocco PR. Mesenchymal  stem cell trials for 
pulmonary diseases.  J Cell Biochem. Jun 2014;115(6):1023-1032.
92. Kean TJ, Lin P,  Caplan AI, Dennis JE. MSCs: Delivery Routes and  Engraftment, 
Cell-Targeting Strategies, and Immune  Modulation. Stem  Cells Int. 
2013;2013:732742.
93. Cassileth PA, Harrington  DP, Appelbaum  FR, et al. Chemotherapy compared  with  
autologous or allogeneic bone  marrow transplantation in  the management of  acute 
myeloid leukemia in first remission. N Engl J Med. Dec 3 1998;339(23):1649-1656.
94. Phillips GL, Herzig RH, Lazarus HM, et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total  body irradiation, and  transplantation of 
cryopreserved autologous marrow. N Engl J  Med. Jun 14 1984;310(24):1557-1561.
95. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations  of respiratory symptoms and on pulmonary 
function in patients with  cystic fibrosis. The Pulmozyme Study Group.  
N.Engl.J.Med. 9/8/1994 1994;331(10):637-642.
Revision History Log
Protocol CF-MSC-01 Confidential
Version 1.13                      Version Date: 17Dec2019 73 of 73Revision Number
Revision or UpdateDate of Release (ddMMMyyyy)
Approver
1.12Employment of Revision History Log  for 
document control purposes.
Sponsor Investigator  transfer from James 
Chmiel to Erica Roesch. 
Inclusion Criteria changed (#4) FEV ≥ 50% predicted to ≥ 40%  predicted.01NOV2018Laura Dixon
1.13Section 9.4.2 updated to indicate bone  marrow  
collection will  take place within 7 days of 
infectious disease testing. 17DEC2019Laura Dixon